Cover photo courtesy of Creative Agency: Zaki Rose, Photographer: Carlos Cruz.
Richard Sherman, American football star and brand ambassador for
Tekcapital’s portfolio company Lucyd ltd.
Tekcapital PLC
Registration #: 08873361
Stock Code: TEK
Risk Factors and Forward Looking Statements
The information contained in this document has been prepared and distributed by the Company and is subject to material updat-
ing, completion, revision, verification and further amendment. This Report is directed only at Relevant Persons and must not be
acted on or relied upon by persons who are not Relevant Persons. Any other person who receives this Report should not rely or
act upon it. By accepting this Report the recipient is deemed to represent and warrant that: (i) they are a person who falls within
the above description of persons entitled to receive the Report; (ii) they have read, agree and will comply with the contents of this
notice. The securities mentioned herein have not been and will not be, registered under the U.S. Securities Act of 1933, as amended
(the “Securities Act”), or under any U.S. State securities laws, and may not be offered or sold in the United States of America or its
territories or possessions (the “United States”) unless they are registered under the Securities Act or pursuant to an exemption
from or in a transaction not subject to the registration requirements of the Securities Act. Neither this Report nor any copy of it
may be taken or transmitted into the United States, or distributed, directly or indirectly, in the United States, or to any “US person”
as defined in Regulation S under the Securities Act of 1933, including US resident corporations or other entities organised under
the laws of the United States or any state thereof or non-U.S. branches or agencies of such corporations or entities. This Report is
not being made available to persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any other
jurisdiction in which it may be unlawful to do so and it should not be delivered or distributed, directly or indirectly, into or within
any such jurisdictions.
Investors must rely on their own examination of the legal, taxation, financial and other consequences of an investment in the Com-
pany, including the merits of investing and the risks involved. Prospective investors should not treat the contents of this Report
as advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers concerning
any acquisition of shares in the Company. Certain of the information contained in this Report has been obtained from published
sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other par-
ties which have been made available to the Company. The Company has not carried out an independent investigation to verify the
accuracy and completeness of such third party information. No responsibility is accepted by the Company or any of its directors,
officers, employees or agents for the accuracy or completeness of such information.
All statements of opinion and/or belief contained in this Report and all views expressed represent the directors’ own current as-
sessment and interpretation of information available to them as at the date of this Report. In addition, this Report contains certain
“forward-looking statements”, including but not limited to, the statements regarding the Company’s overall objectives and strate-
gic plans, timetables and capital expenditures. Forward-looking statements express, as at the date of this Report, the Company’s
plans, estimates, valuations, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance.
Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company’s control, and
there can be no assurance that such statements will prove to be accurate. No assurance is given that such forward looking state-
ments or views are correct or that the objectives of the Company will be achieved. Further, valuations of Company’s portfolio
investments and net asset value can and will fluctuate over time. The reader is cautioned not to place reliance on these statements
or views and no responsibility is accepted by the Company or any of its directors, officers, employees or agents in respect thereof.
The Company does not undertake to update any forward-looking statement or other information that is contained in this Report.
Neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or
will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of,
the accuracy or completeness of the information contained in this Report or for any of the opinions contained herein or for any
errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Report. Neither the issue of this Report
nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or
the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discus-
sions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses
or expenses incurred in connection with any appraisal or investigation of the Company. This Report should not be considered a
recommendation by the Company or any of its affiliates in relation to any prospective acquisition of shares in the Company. No
undertaking, Report, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or any of its
affiliates, any of its directors, officers or employees or any other person as to the accuracy, completeness or fairness of the informa-
tion or opinions contained in this Report and no responsibility or liability is accepted for any such information or opinions or for
any errors or omissions.
© Copyright Tekcapital Plc 2019
PAGE
4
5
6
8
9
10
12
13
14
15
16
22
23
24
26
32
33
34
35
36
37
38
CONTENT
BUSINESS OVERVIEW
Overview
Investment Case
Key Highlights
Q&A with our Executive Chairman
Tekcapital at a Glance
STRATEGIC REPORT
Chairman’s Summary
IP Market
Our Services
What Our Clients and the Press Say
Financial Review & Key Performance Indicators
Portfolio Review
Board of Directors
DIRECTORS REPORT
Directors’ Report
Directors’ Remuneration Report
OUR FINANCIALS
Independent auditor’s report
Consolidated Statement of Comprehensive Income
Consolidated Statement of Financial Position
Company Statement of Financial Position
Consolidated Statement of Changes in Equity
Company Statement of Changes in Equity
Consolidated Statement of Cash Flows
Notes to the Financial Statements
3
TEKCAPITAL COMMERCIALISES UNIVERSITY IP AND
PROVIDES IP SERVICES TO UNIVERSITIES AND CORPORATES
Tekcapital Group’s goal is to create value from its ability to
identify, acquire and commercialise promising new
university IP. Additionally, to assist our clients, keep our finger
on the pulse of new discoveries and reduce operating costs,
we provide technology transfer investment services to
companies and universities worldwide.
Using our proprietary global university network, we provide
services to universities and companies to help them
commercialize their innovations. Over the past three years,
using these services, we have built a compelling group of
portfolio companies to commercialize high value properties we
have uncovered.
We believe that when you couple commercialization ready,
compelling university IP with strong senior management,
vibrant companies will emerge, returns on invested capital will
outperform the sector and exits will occur faster. When we realise
exits the Group’s goal is to distribute the majority of proceeds as
a special dividend to our shareholders.
4
www.tekcapital.com INVESTMENT CASE
WORLD’S LARGEST
NETWORK OF UNIVERSITY IP
4,500 UNIVERSITIES
Total revenue
including fair value
gains $6.8m
Profit after tax
$4.6m
SOLID, MULTI-SECTOR DUE DILIGENCE
CAPABILITY
60 SCIENTISTS
Net assets
$16.1m
NUMBER OF INDUSTRY LEADERS
RECRUITED BY PORTFOLIO COMPANIES
8 INDUSTRY LEADERS
NUMBER OF PORTFOLIO COMPANIES
ADDRESSING $1B+ MARKETS
4 PORTFOLIO COMPANIES
Compound Annual
Growth Rate of Net
Assets
75%
Return on Assets
(ROA)
33%
Return on invested
capital (ROIC)*
30%
*Since floatation in 2014
% of costs covered by
service
revenues
46%
5
KEY HIGHLIGHTS
FINANCIAL
Our investment objective is to achieve long-term growth of net assets and
returns on invested capital through the commercialisation of university
discoveries. 2018 was the best year for value creation in the Group’s short
history:
• Net Assets increased 51% to US$16.13m, a record level (2017:
US$10.68m)
• Net Assets per share $0.30 (2017: $0.25)
• Total revenue US$6.83m (2017: US$7.26m)
- Revenue from services increased 28% to US$1.04m (2017: US$0.81m)
- Net increase of US$5.79m in fair value of portfolio companies
(2017: US$6.08m)
• Reduction of operating expenses by 29% to $1.72m (2017: US$2.42m)
Service revenues cover ~46% of current cost base
• Profit before tax: $4.55m (2017: $4.15m)
• Placing to raise US$1.16m completed in October 2018
INVESTMENT PORTFOLIO
Net Assets (US$m)
97.5% ownership
• Completed successful test production of its patented salt crystals
• Strengthened the board with the addition of industry experts with relevant experience including
Eduardo Souchon a former brand manager from Pringles®, and Steve McCready, the former director
of product development at Albertsons a leading $60b supermarket chain
• Appointed Victor H. Manzanilla as its CEO. Previously Victor served as marketing director for Office
Depot® and home care marketing innovation manager and brand manager at Procter & Gamble
• Post end of period appointed Javier Contreras as COO to further its commercialization efforts. Javier
has significant experience in developing supply chains with Clorox and other companies
• Conducted focus group testing of consumer packaging
• On track for product launch of low sodium salt and snacks in Q4 2019
www.salarius.co
• Launched its online shop for high-tech and fashionable eyewear
100% ownership
• Launched sales of Lucyd Loud audio glasses, proper prescription glasses that can be
used to listen to music, answer your mobile phone or talk to Siri®
• Launched Turbo Flex, a line of nearly indestructible frames and a range of designer
eyeglasses
• Post end of period appointed Richard Sherman, an American football star, as its Chief
Brand Officer and brand ambassador. The company is planning to launch the Richard
Sherman sunglass line in Q3 2019
• On track to launch Lucyd Loud 2.0 in 10 designer styles in Q2 2019
• Launched global affiliate and reseller program
• Filed a patent application for enhancing Lucyd Loud with a smart watch display
www.lucyd.co
6
www.tekcapital.com
PORTFOLIO COMPANIES
Net Assets (US$m)
www.guident.co
100% ownership
• Acquired exclusive licence to U.S. patent #9,429,943 from Florida A&M. Patent enables
the development of software apps for controlling autonomous vehicles using AI
• Appointed Harald Braun as its Chairman. Mr. Braun has served as CEO of Siemens
Networks USA amongst other relevant executive roles
• Post end of period appointed Johan De Nysschen and Daniel Grossman as directors. Mr.
De Nysschen recently served as Executive Vice President of General Motors and
President of Cadillac Division. Daniel Grossman helped create General Motors’ mobility
division, “Maven”, and led all operations as COO, was a Vice President at Zipcar, which
was subsequently sold to Avis Budget for ~$500m
www.salarius.co
• Continued progress with its unique and patented portable
oxygen concentrator (POC) programme.
29% ownership
• Added Dr. Paul Bray as Vice President of Operations (previously at St. Jude Medical)
www.belluscura.com
• Belluscura seeks to receive 510(K) clearance from the US FDA in Q3 2019
• The POC market is currently valued at US$1.4b per year .
• Post end of period, Belluscura filed an additional patent application entitled “Im
proved Extracorporeal Membrane Oxygenation Device, System and Related Methods,”
which involves incorporating and expanding their existing oxygen enrichment patent
portfolio into an innovative, next generation portable artificial lung and a novel
wound care treatment device.
CORPORATE
Continued growth of technology transfer services. Added two new services, technology commercialization training and a new Invention
Evaluator report customized for startups:
Invention Evaluator has developed a new report at the request of StartUp Chile, the leading start-up accelerator in Latin
America. Start-Up Chile supports several hundred companies a year, and these reports will assist their start-up companies on
an ongoing basis.
Successfully developed and delivered an advanced technology commercialization programme in Santiago, Chile with HUB
APTA and the Chilean Biotechnology Association. This programme provided training services, Invention Evaluator reports and
our software apps to our Chilean customers. The programme included participants from 13 Chilean research universities and
two other research institutions. The sponsor of this unique programme was the Chilean government Agency CORFO, the main
Chilean agency focused on entrepreneurship, innovation and competitiveness. University training programmes represent a
new line of service business for Tekcapital, and we are optimistic about delivering more of them in future periods.
Appointed Michael Rosen as Managing Director of Academic Training to accelerate growth in the LATAM market. Mr. Rosen has worked
with leading research universities, and held senior management positions with Pfizer, Bristol-Myers Squibb and Searle/Monsanto.
Appointed Eduardo Giacomazzi as business development advisor in Brazil. Eduardo was the founder and director of the Brazilian
Biotechnology Association and co-author of Brazil Biotech map.
7
“I’M DELIGHTED TO REPORT THAT THROUGH THE
COLLECTIVE EFFORTS OF OUR DEDICATED AND
CAPABLE TEAM WE HAVE ACHIEVED RECORD NET
ASSETS IN 2018.”
DR CLIFFORD M. GROSS
Q&A WITH OUR EXECUTIVE CHAIRMAN
Q: What do you consider the most important milestone reached by Tekcapital Group this year?
A: The advancement of our portfolio companies, Belluscura, Lucyd, Salarius and Guident coupled with
improved service revenues has taken the Company to a new level of financial performance.
Q: What makes Tekcapital a better investment case than comparable companies in the IP sector?
A: By having the largest university IP sourcing network and the largest scientific advisory board to screen
these properties, we believe we are better positioned in the difficult business of picking early-stage winners.
In addition, by providing technology transfer services to other companies and universities, we are able to
keep our finger on the pulse of new innovation globally whilst covering about 46% of our costs.
Q: How was Tekcapital able to attract so much high caliber talent in 2018?
A: I think Victor Hugo said it best, “Nothing is more powerful than an idea whose time has come.”
Q: What risks do you see in the IP industry related to Tekcapital?
A: The single biggest risk is the availability of patient capital in the UK to nurture and commercialise the
disruptive university technologies we are able to acquire.
Q: What are the main goals for the Group when it comes to portfolio companies but also the tech-transfer
service side of the business?
A: Our main investment focus is to select and commercialise technologies in our portfolio companies that can
be disruptive in their markets by reducing costs and improving the quality of life of our customers. When we
realise exits the Group’s goal is to distribute the majority of proceeds as a special dividend to our
shareholders. Simultaneously, we strive to grow our service revenues, so that over time they will cover our
day-to-day operating expenses, freeing up more capital for investment.
8
www.tekcapital.com
TEKCAPITAL AT A GLANCE
T
ekcapital has built the largest university IP network in the world, coupled with a high-caliber team responsible
for market-ready technology selection. The Group provides universities and corporate clients with a wide range
of technology transfer services while simultaneously selecting compelling technologies for its own portfolio,
for subsequent commercialization. We believe this unique combination provides a competitive advantage in
the sector, as we both use and sell our IP investment services. This keeps us close to our technology suppliers
and allows the company to reduce its operating expenses.
TEKCAPITAL’S FORMULA OF MARKET READY IP COMBINED WITH LEADING TALENT POSITIONS
THE GROUP FOR LONG-TERM GROWTH AND INCREASES THE PROBABILITY OF MEANINGFUL
EXITS
Value of investment portfolio (US$m)
WORLD’S LARGEST NETWORK OF UNIVERSITY IP. WE CAPTURE APPROXIMATELY 80% OF WORLD’S
UNIVERSITY-DEVELOPED IP FROM 4,500 RESEARCH INSTITUTIONS ACROSS 160 COUNTRIES
9
STRATEGIC REPORT
Chairman’s Summary
Tekcapital brings innovations from lab to market. In 2018,
several of our portfolio companies have made significant
progress and we have almost doubled the value of our
holdings. We have also grown our service revenues by 28%,
including portfolio company management fees and R&D
related tax credits, with storied clients like General Electric and
a wide variety of research institutions. As a result, our profits
and net assets ended the year at record levels.
Key Portfolio companies
Using our proprietary global university network, we
provide services to universities and companies to help them
commercialize their innovations. Over the past three years,
using these services, we have built a compelling group
of portfolio companies
to commercialize high value
properties we have uncovered. We believe that when you couple
commercialization ready, compelling university IP with strong
senior management, vibrant companies will emerge, net
assets will grow, returns on invested capital will outperform
the sector and exits will occur faster. When we realise
exits the Group’s goal is to distribute majority of proceeds as a
special dividend to our shareholders.
Salarius is a food tech business that owns a patented process
to produce what are probably the world’s smallest edible salt
crystals. These small crystals dissolve faster on the tongue,
so you need to use less salt, while still having that salty taste
consumer’s love. Less salt means about 50% less sodium.
Less sodium means a reduced likelihood of developing heart
disease, the world’s number one killer. Post-period, Salarius
has added additional senior management with Fortune 500
company manufacturing experience, and is expected to launch
pilot production of Salarius salt by Q2 and begin selling Salarius
salt and snacks in Q4. According to Future Market Insights¹, the
low sodium ingredient market is estimated to reach US$1.76bn
by 2025. Tekcapital owns 97.5% of Salarius.
Lucyd has built a new, online eyeglass business that combines
technology with traditional eyewear. Recently they introduced
Lucyd Loud 1.0 their first proper prescription glasses that you
can use to answer your phone, listen to music and talk with Siri®.
The product has been well received and the company is focused
on launching Lucyd Loud 2.0 in Q2 with a range of fashion for-
ward designs. Post end of period they engaged Richard Sher-
man, the American football star as a brand ambassador, and will
introduce a line of athletic sunglasses that he will help curate in
Q3. According to Statista2, the current online market for eyewear
is $3.8b per year. Tekcapital owns 100% of Lucyd.
Guident owns an exclusive licence to a patented technology
that enables the development of software apps for controlling
autonomous vehicles. Guident has engaged Harald Braun as its
Chairman. Harald was CEO of Siemens Networks USA. Post end
of period they have added Johan De Nysschen to their board,
the former executive VP of General Motors and president of
the Cadillac Motor division. Additionally, they have also added
Daniel Grossman as a director. Dan helped create General Mo-
tors’ mobility division, “Maven”, and led all operations as COO,
and was a Vice President at Zipcar, where he helped pioneer
the brand globally. Previously Dan was CEO of Chariot. Guident
plans to launch the company website in Q1 and their out-licens-
ing program in Q2 2019. According to Statista, the US market for
Autonomous vehicles is projected to reach $6 billion by 20253.
2018
1- https://www.futuremarketinsights.com/reports/sodium-reduction-ingredient-market
2- https://www.statista.com/outlook/12000000/109/eyewear/united-states#market-onlineRevenueShare
3- https://www.statista.com/statistics/428692/projected-size-of-global-autonomous-vehicle-market-by-
vehicle-type/
10
FINANCIAL PERFORMANCE
2018 was the best year for value creation in the Group’s short history. A 51%
increase in net assets fueled by an 88% increase of the NAV of its portfolio
companies was further aided by a 28% increase in service revenue. The Group
was able to accomplish this whilst simultaneously reducing its cost-of-sales by
19% and administrative costs by 29%. The Group has now demonstrated two
consecutive years of growth in Net Assets and service revenue.
Due to the quickening pace of innovation, patented, exgenously developed
university technologies are a valuable currency. As a result, we continue to
believe that the market opportunity for the Group is both large and should
continue to grow apace in lock-step with our portfolio companies.
www.tekcapital.com STRATEGIC REPORT
Tekcapital owns 100% of Guident.
Belluscura has developed an improved portable oxygen concentrator to provide on-the-go supplemental O2. We believe
that their patented device will be smaller, lighter and quieter then competitive products and will have a replaceable filter
cartridge that will allow the user to upgrade the unit as their disease progresses. Belluscura anticipates they will receive
FDA clearance for their device and begin sales in late 2019. Post end of period, Belluscura, in conjunction with its exclu-
sive research partner Separation Design Group, has expanded its oxygen therapy technology with the filing of a patent
application covering oxygen enrichment inventions relating to a portable artificial lung and wound care devices. The lat-
est patent application, entitled “Improved Extracorporeal Membrane Oxygenation Device, System and Related Methods,”
involves incorporating and expanding their existing oxygen enrichment patent portfolio into an innovative, next genera-
tion portable artificial lung and a novel wound care treatment device. According to Global Market Insights, the medical
portable O2 market is currently $1.4bn a year and growing by more than $100m/year1 . Upon receipt of clearance from the
FDA, the Directors believe that Belluscura’s value should significantly increase. Tekcapital owns 29% of Belluscura.
In 2018 we closed three portfolio companies that we did not think could create value for TEK shareholders, allowing
capital to be allocated to projects with higher potential returns.
Corporate
In 2018 we continued with the expansion of Invention Evaluator® and other services into Latin America. We also added
two new services, technology commercialization training and an Invention Evaluator report customized for startups.
Currently, approximately 46% of our expenses, including cost of sales, are now covered by our service revenue. Our
goal over the next few years is to have all of our operating costs covered by our service revenues. To help achieve this
we have expanded our business development team. We appointed Michael Rosen as Managing Director of Academic
Training to accelerate growth in the LATAM market. Mr. Rosen worked with leading research universities, and held senior
management positions with Pfizer, Bristol-Myers Squibb and Searle/Monsanto. Additionally, we added Eduardo
Giacomazzi as business development advisor in Brazil. Eduardo was the founder and director of the Brazilian
Biotechnology Association and co-author of Brazil Biotech map.
Current Trading and Outlook
Having continued to develop and expand Tekcapital’s existing business, the Board is confident that continued investment
in our portfolio companies remains the right strategy. Additionally, we are also exploring a new potential investment in
cannabidiol intellectual properties to address the current market demand. Further, we are executing on our strategy and this
should result in increases in returns on invested capital as our portfolio companies continue to grow. Whilst it is clear that
the Company is progressing well, we anticipate fluctuations in our net asset values from period to period due to individual
portfolio company performance, valuations and changes in market conditions and macro-economic financial conditions.
We are grateful for the patience and support of our shareholders. We are also sincerely appreciative of our dedicated,
creative and hardworking team without which, none of the results reported herein would be possible. In the spirit of
Helen Keller who said “Alone we can do so little; together we can do so much,2” I would like to commend the terrific
contributions of the following individuals: Eric Cohen, Melissa Cruz, Konrad Dabrowski, Harrison Gross, Max Inglis, Maria
Kowalski, Selwyn Lloyd, Michael Manion, Michael Rosen and Amy Shim.
Dr Clifford M Gross
Executive Chairman
13 March 2019
1 https://www.gminsights.com/industry-analysis/medical-oxygen-concentrators-market-report
2https://www.amazon.com/Helen-Teacher-Story-Keller-Sullivan/dp/0891282343
11
THE IP MARKET
Historical Foundation of the market
“Intellectual property (IP) has been very important to the UK
for a long time. The first trademark legislation was passed by
the English Parliament in 1266. The UK was at the forefront
of developing patent rights and the first to codify copyright
law with the Statute of Anne in 1710. It has made good use
of these IP rights ever since they were brought into being.”
Baroness Neville-Rolfe
Former Minister for Intellectual Property, Department for Busi-
ness, Energy and Industrial Strategy, U.K.¹
Current market challenges and opportunities
The world has become smaller and
the pace of
innovation is quickening. As such, we have expanded our
footprint to include IP not only from universities in the UK
but from all member states of the World Intellectual Property
Organization. This university idea factory is pumping on
all cylinders and creating innovations in every area of
science, technology and medicine. However, without the
access to patient capital and experienced management,
most of these
lie fallow. Tekcapital’s
approach is to carefully select high-value innovations that
are ready for market, and nurture them with experienced
management, often from Fortune 500 companies, as this
mitigates go-to-market risk. To-date, we believe our early
results have shown great promise. Overall, about 30% of the
value of the world’s products comes from intellectual capital,
which is almost twice the contribution from tangible capital.
Utilizing new IP and brainpower is exactly how a company
like Uber can become more valuable, in a short period, than
most of the major automobile companies combined.
innovations will
According to the Association of University Technology
Managers (AUTM)² in the U.S. in 2017, 1,080 university
spin-outs were formed … and more than $3 billion in licens-
ing revenue were reported, the highest annual amount so far.
Approximately 70% of university
innovations are
commercialized through university spinouts. This is a dra-
matic change in the tech-transfer industry, where just a few
years ago, only about 10% of university innovations were
licensed through spinout companies. We believe that this
change has resulted primarily from two factors; the avail-
ability of low-cost capital due to historically low interest
12
rates and the preference of large companies to consummate
acquisitions of early-stage companies that have de-risked new
technologies and could deliver a more meaningful financial
impact.
Perhaps the best example to-date is Google.
“In 1996, Stanford University graduate students Larry Page
and Sergey Brin created PageRank, which led to a new search
engine called Google. After Google incorporated in 1998,
Stanford licensed the PageRank algorithm to the new start-up. In
just two years, Google became the world’s largest search engine,
with more than 1 billion webpage addresses in its index. The
company completed an IPO in 2004.”³
Tekcapital is keenly focused of finding and commercializing
university discoveries for its own portfolio as well as for its
clients. We believe the future is extremely bright for our
business, because many of the greatest discoveries are from
the world’s research institutions, to which we have unfettered
is our
access. Efficiently harvesting
passion. Of course, not every portfolio company will win or even
survive, but this doesn’t deter us, as we don’t define ourselves by
our failures but rather the few successes that can meaningfully
contribute to improving the quality of life, whilst creating value
for our shareholders.
these discoveries
“The Invention Evaluator tool has helped us to make decisions with
a greater degree of certainty of the path that our technology should
follow.” Jorge Darlas Ejecutivo de Transferencia de Tecnología y
Licenciamiento, Concepción, Chile
“Their analysis of our IP has been very useful to provide a clear
vision of our technologies.” Daniela Fuentes, Directora, Dirección
de
Innovación y Transferencia Tecnológica, Vicerrectoría de
Investigación, Santiago, Chile
SOURCES
¹WIPO Magazine (2016) Geneva
²AUTM US Licensing Activity Survey: 2017
³WIPO World Intellectual Property Report 2017: Intangible
capital in global value chains. Geneva
www.tekcapital.com
OUR SERVICES
and
recruit
Commercializing university innovations is challenging
and requires well-honed skills and specialized tools to be
successful and scalable. According to the Association of
University Technology Managers (AUTM) less than 1% of
university patents generated revenues of > $1m¹ in
2017. This indicates that to be successful in the space
it
is necessary to mitigate selection bias, conduct
detailed and thorough due diligence, assess the market
commercialization
potential properly
executives with
significant experience. Tekcapital’s
services have been built to address each of these points.
Our global discovery network covers 4,500 institutions in
160 countries, and our search app makes it easy to identify
IP,
their
respective disciplines for hands-on due diligence, our
invention evaluator reports are the industry standard for
assessing market potential of university IP and more than
5,000 have been delivered to institutions worldwide, and
our in house recruiter Vortechs Group is a recognized
leader in recruiting tech-transfer executives. We use these
services to both help our clients and to enhance our
returns on invested capital for our portfolio companies.
scientists
experts
our
are
60
in
INVENTION EVALUATOR
Rapid, objective reports that assess the
market potential of any new technology.
Combines human analysts with unique
research algorithms.
IP SEARCH APP
Instantly
IP
search
search
Global University
and
app.
index worldwide university PCT
applications and patents on
your smartphone.
IP ACQUISITION
OPPORTUNITIES
Acquire disruptive, curated
university IP that’s ready for
market, directly from our
portfolio.
VORTECHS GROUP
Executive Recruiting Firm
Specializing In Technology
Transfer executives.
TEK TRAINING
Custom solutions
for building
new tech transfer offices, spin
out companies, and accelera-
tors. For tech transfer specialists,
research centers and government
SOURCES
¹ AUTM US Licensing Activity Survey: 2017
13
WHAT OUR CLIENTS AND THE PRESS SAY
“What you do is disruptively high quality at a value no one
else has been able to touch.” Jeff Amerine
effective way
“Invention Evaluator provides an extremely
cost
through
technologies to see which ones fit our criteria.”
Dr. Craig Patch
screen
to
“We would recommend Invention Evaluator reports to
any organization looking to commercialize technologies,
especially for technologies outside of the core expertise
of the office. The benefit to value ratio is very high,
the reports are thorough, timely and in a format that
is easy to understand and share with investors.” Lisa
Lorenzen
“We have had a great experience with the results
of the studies we requested.” “Hemos tenido una
muy Buena experiencia con los resultados de los
estudios que hemos solicitado” Patricia
Anguita
“As a portfolio management tool for busy technology
transfer office, Invention Evaluator makes great sense.”
Rohan McDougall, Curtin University of Technology
“In a few short weeks, the Vortechs Group presented us with
more and better qualified candidates than we were able to
find on our own in the previous six months of searching.
Thanks to their expertise, we were able to find and hire the
one-of-a-kind candidate we were looking for to lead our
Technology Transfer efforts”
Tekcapital helps companies of all sizes find and acquire
university discoveries to create market value. We have found
their offering to be well received by our listed companies that
have tried their service. Paul Dorfman, Managing Director
“Invention Evaluator is very responsive to our
needs, delivering our reports in a timely manner”
Dr. Fiona Cameron, University of Western
Sidney
“With their technology transfer recruiting expertise, The
Vortechs Group contributed to our process of finding
candidates whom we otherwise might never have seen,
ultimately leading to a successful hire. It was a pleasure
partnering with The Vortechs Group and I recommend
their services to organizations seeking technology
transfer and related positions.”
Julian Mitchell- “In addition to a growing portfolio
of university IP (UIP) investments, Tekcapital helps
research institutions and businesses develop disruptive
technologies and expand their portfolios of intellectual
capital through leveraging their suite of powerful and
convenient technology transfer services.”
“Drew Hendricks- “Tekcapital released an app earlier
this year that allows users to search for IP from their
smartphones. This is a good way to get a feel for what is
out there, identify technology you may want, and get your
creative wheels spinning.”
Nick Hastreiter, “An entrepreneur who wants to benefit
from UIP would traditionally have to network with
individual universities, making relationships with their
Technology Transfer Offices. But today entrepreneurs and
international organizations facilitate a near frictionless
system of access to that wealth of innovation.”
14
www.tekcapital.com FINANCIAL REVIEW & KEY PERFORMANCE
INDICATORS
THE KEY PERFORMANCE INDICATORS (KPI) FOR THE GROUP
The Key Performance Indicators (KPIs) listed below represent those that are typically applied to companies that seek to commercialise
university technologies and serve as a starting point for evaluating the Group’s performance:
KPI
DESCRIPTION
2018 PERFORMANCE
2017 PERFORMANCE
FAIR VALUE OF
THE PORTFOLIO
TOTAL REVENUE
Updated value of portfolio com-
panies using costs, independent
valuations or observed third party
investments
Service revenue plus change in fair
value of portfolio
PROFIT
After tax profit
NET ASSETS PER
SHARE
Total assets minus total liabilities
per share
ROIC
Returns on invested capital since
flotation in 2014
Net Assets (US$m)
$13.7m
$7.3m
$6.8m
$4.6m
$0.30
30%
$7.3m
$4.2m
$0.25
47%
Three out of five of our Key Performance Indicators showed
improvement in 2018. The Group has now demonstrated two
consecutive years of growth in Net Assets and Net Assets per
share.
The Group’s cash position at the end of the period is US$1,165,442
with modest liabilities as costs have been settled without delay
using available funds. The Group had no debt as of 30 November
2018.
Profit after tax (US$m)
The Group’ has also demonstrated consistent growth in revenue
from services. The Group was able to achieve this growth while
simultaneously
its administrative expenses by
US$699,714 in 2018.
reducing
Directors do not believe there are any material environmental
issues that need to be reflected in our KPIs for 2018.
The Group has received a R&D Tax Relief Credit for the total of US$0.1m during the year in connection to following R&D activities:
- The design and development of a unique and first of a kind Innovation Discovery Network solution, developed to facilitate an
improved technology search engine
- The Report Builder to develop and test new invention report templates and revamp the invention evaluator bespoke software
- The Invention Evaluator migration and integration with bespoke customer portal.
15
PORTFOLIO REVIEW
PATENTED LOW-SODIUM SALT
• Salarius is taking the lead in the industry bringing the best low-sodium salt
solution based on a mechanical transformation of the salt grain itself. This
solution is the only one that delivers the exact salt flavor, because it is salt.
The technology breaks the salt grains into a size that is one hundred times
smaller than a typical grain, delivering a powerful saltiness as the micro-grains
dissolve in mouth with appx. 50% less salt consumption.
• Recent successful sample production and independent taste testing indicates
Salarius salt delivers all of the flavour with roughly half of the sodium.
• On 22nd May 2018 Salarius announced the addition of Eduardo Souchon
(formerly at Pringles) and Steve McCready (formerly at Albertsons) to its board.
• On 1 August 2018, Victor H. Manzanilla appointed as CEO of Salarius.
Mr. Manzanilla previously served as Marketing Director of Office Depot an
office products chain with approximately 1,400 stores, and Brand Manager
at Procter & Gamble. Mr. Manzanilla has purchased 2.5% of the shares of
Salarius for $50,000.
The low sodium ingredient market is estimated to reach US$1.76bn by 2025
according to Future Market Insights1.
Goal: Launch low sodium salt and snacks in Q4 2019.
Tekcapital owns -
97.5% of Salarius Ltd
97.5%
ON 1 AUGUST 2018, SALARIUS LTD APPOINTED VICTOR H.
MANZANILLA AS ITS CEO. FORMERLY MARKETING DIRECTOR
AT OFFICE DEPOT AND BRAND MANAGER AT PROCTER &
GAMBLE
16
SOURCE
¹ https://www.futuremarketinsights.com/reports/sodium-reduction-ingredient-market
www.tekcapital.com
PORTFOLIO REVIEW
ON 22ND MAY 2018, SALARIUS LTD APPOINTED EDUARDO
SOUCHON AS A DIRECTOR. EDUARDO HAS 20 YEARS OF
BUSINESS, BRAND AND MARKETING EXPERIENCE FOCUSED
ON SNACKS (PRINGLES®), HEALTH PRODUCTS AND OFFICE
SUPPLIES IN THE CONSUMER PACKAGED GOODS AND THE
RETAIL INDUSTRY (PROCTER & GAMBLE)
ON 22ND MAY 2018, SALARIUS LTD APPOINTED STEVE
MCCREADY AS A DIRECTOR. PREVIOUSLY STEVE
SERVED AS DIRECTOR OF PRODUCT DEVELOPMENT AT
ALBERTSON’S COMPANIES, A LEADING U.S. SUPERMARKET
COMPANY WITH MORE THAN $60BN IN SALES AND 2,300
17
PORTFOLIO REVIEW
LUCYD: THE CLEAR CHOICE FOR TECH EYEWEAR
• Unique value proposition: advanced
technology eyewear with Rx combined
with an improved online experience,
competitive pricing.
• Aug. 2018 Launched an online eShop
to provide cutting-edge prescription
spectacles. The eShop offers Lucyd Loud
a Bluetooth pair of Rx glasses with
bone conducting speakers that allows
the user to answer their phone, listen
to music and speak with Siri®.
• Oct. 2018 Formed first reseller partner
ship with a Brazilian optical retailer.
• Nov. 2018 Launched global affiliate &
reseller program with over 70 affiliates
signed in the first week.
• Dec. 2018 appointed Richard Sherman
an American football star, as its Chief
Brand Officer and brand ambassador.
Goal: Develop a successful global
eShop focused on upgrading your
eyewear with advanced technology.
The current online market for eye-
wear is $3.8b according to Statista1.
Tekcapital owns -
100% of Lucyd ltd
100%
ON 3 DECEMBER 2018 LUCYD LTD APPOINTED RICHARD
SHERMAN, AMERICAN FOOTBALL STAR AS CHIEF BRAND
OFFICER AND BRAND AMBASSADOR
SOURCES
¹ Statista.com - US Eyewear Market, Online Revenue Share
Photo courtesy of Creative Agency: Zaki Rose, Photographer: Carlos Cruz.
18
www.tekcapital.com PORTFOLIO REVIEW
PREMIUM MEDICAL DEVICES AT VALUE PRICES
• Unique medical device company that has developed an improved
portable oxygen concentrator to provide on-the-go supplemental O2,
EXPLO2R
• Capable & highly experienced management: Bob Rauker, CEO
(previously Boston Scientific) & Dr Raymond Bray, VP
(previously St. Jude Medical).
• According to Global Market Insights, the medical portable O2
market is expected to grow from $1.4bn ISN 2018 to $2.4bn
by 2024. Largest competitor valued at $4B.
Goal: File 510K with US FDA and receive clearance Q3 2019 for
the EXPLO2RE, potentially one of the most advanced portable
oxygen concentrators in the world.
The medical portable O2 market is expected to grow
from $1.4bn this year to $2.4bn by 2024¹
$2.21bn
$2.01bn
$1.83bn
$2.41bn
$1.66bn
$1.51bn
$1.40bn
2018 2019 2020 2021 2022 2023 2024
¹ https://www.gminsights.com/industry-analysis/medical-oxygen-
concentrators-market-report
Tekcapital owns ~
29% of Belluscura plc.
29%
EXPLO2RE PORTABLE
OXYGEN CONCENTRATOR
Lightest:
Only 1.25kg (2.8lbs)
Most Efficient:
32% more O2 per pound
Quiet:
Reliable:
Modular:
Low Cost:
Only 39 dB
Long battery duration
Only expandable POC
with consumer replaceable filter cartridges
Projected 70% cost savings over
duration of the disease
Strong IP:
13 patents and applications
19
PORTFOLIO REVIEW
AUTONOMOUS VEHICLE VALET
• Acquisition of exclusive license to U.S. Patent #9,429,943 from FMAU that enables
the development of software apps for controlling autonomous vehicles using
artificial intelligence.
• Using this patented technology Guident is enabled to develop apps that allow
user’s of autonomous vehicles to dispatch their vehicles to join ridesharing fleets,
find available parking spots and charging stations and report accidents as well as
park themselves.
• On 2nd October, 2018, Guident announced Harald Braun was appointed as its
Chairman. Mr. Braun has served as CEO of Siemens Networks USA (NYSE: SI) and
Aviat Networks (NASDAQ: AVNW).
• Post period end: On 6th December, 2018, Guident announced that Johan De Nyss
chen was appointed as a director. Johan previously served as Executive Vice
President of General Motors and President of the Cadillac Motor Division, President
of Infiniti Motor Company Ltd, President of Audi of America Inc., and President of
Audi Japan, amongst other positions.
• Post period end: On 14th January, 2019, Guident announced that Daniel Grossman
was appointed as a director. Daniel is currently CEO of Chariot, the ride sharing
company that was acquired by Ford in 2016. Prior to Chariot, Dan helped create
General Motors’ mobility division, Maven, and led operations as COO, and was a Vice
President at Zipcar prior to its sale to Avis.
Goal: Develop and provide apps with licensed technology to autonomous
vehicle manufacturers.
Tekcapital owns -
100% of Guident Ltd
100%
ON 2ND OCTOBER, 2018 GUIDENT LTD APPOINTED HARALD
BRAUN AS ITS CHAIRMAN. MR. BRAUN HAS SERVED AS CEO OF
SIEMENS NETWORKS USA (NYSE: SI) AND AVIAT NETWORKS
(NASDAQ: AVNW). HE SERVED ALSO AS A SENIOR EXECUTIVE AT
NOKIA SIEMENS NETWORKS, NORTH AMERICA.
20
www.tekcapital.com
PORTFOLIO REVIEW
ON 6TH DECEMBER 2018 GUIDENT LTD APPOINTED JOHAN
DE NYSSCHEN AS A DIRECTOR. JOHAN PREVIOUSLY SERVED
AS EXECUTIVE VICE PRESIDENT OF GENERAL MOTORS AND
PRESIDENT OF THE CADILLAC MOTOR DIVISION, PRESIDENT
OF INFINITI MOTOR COMPANY LTD, PRESIDENT OF AUDI OF
AMERICA INC., AND PRESIDENT OF AUDI JAPAN.
ON 14TH JANUARY, 2019 GUIDENT LTD APPOINTED DANIEL
GROSSMAN AS A DIRECTOR. HE MOST RECENTLY SERVED
AS CEO OF CHARIOT. PREVIOUSLY, DAN HELPED CREATE
GENERAL MOTORS’ MOBILITY DIVISION, “MAVEN”, AND LED ALL
OPERATIONS AS COO, AND WAS A VICE PRESIDENT AT ZIPCAR,
WHERE HE HELPED PIONEER THE BRAND GLOBALLY. ZIPCAR
WAS SUBSEQUENTLY SOLD TO AVIS-BUDGET FOR ~ $500M.
21
BOARD OF DIRECTORS
Cliff is a successful executive with 25 years of leadership experience in academia and
commercial enterprises. He is passionate about the development and commercialization
of intellectual property to improve the quality of life and create lasting value. Previously,
he founded Biomechanics Corp and UTEK where he served as CEO and Chairman and
was President and CEO of Innovacorp, the provincial venture capital fund of Nova
Scotia. Cliff has served as Acting Director of the graduate program in Biomechanics and
Ergonomics at New York University, Chairman of the Nelson Rockefeller Department
of Biomechanics at the New York Institute of Technology and Research Professor
at the University of South Florida. Recently, he authored Too Good to Fail: Creating
Marketplace Value from the World’s Brightest Minds and is a named inventor on 19
issued patents. Cliff is a Fellow of the National Academy of Inventors and serves on
the board of directors of the State University of New York at Empire State College. He
received his Ph.D. from New York University and an MBA from Oxford University.
Malcolm has worked for many years as a consultant to companies in technology, natural
resources, and general commerce. Following an early career with PwC in London, he
held CFO, COO, and CEO roles in established corporations including the construction
firm now called Arcadis. Recently he has held several non-executive director or chairman
positions and today these include Corps Security, Baronsmead Second Venture Trust,
and Golden Saint Technologies. Malcolm is a Fellow of the Institute of Directors, Fellow
of the Royal Society for the encouragement of Arts, Manufactures and Commerce,
and Fellow of the Institute of Chartered Accountants in England and Wales. He holds
university degrees from St Andrews (MA) and Warwick (MBA).
Bill Payne is a proven, successful international business leader with over 30 years of
executive, non-executive, coaching, mentoring and management experience in both
small, entrepreneurial and large company environments and cultures. Has redefined
business and technology models whilst driving considerable revenue and profit growth
in highly transformational markets. Bill is an NED and NEC, a Venture Capitalist and a
visiting Professor of several top business schools, as well as having his own successful
executive advisory business. In a 17 year career in IBM his last role was as General
Manager and Vice President of IBM’s Global Customer Service Division with 52000 staff.
He led the disposal of this division to Synnex/Concentrix in 2014. Bill has a Bachelor
of Science Honours degree in Chemical Engineering from Leeds University and is a
Chartered Engineer, a Euro Engineer and is a Fellow of both the Institution of Chemical
Engineers and Royal Society of Arts and Manufacturing.
Robert serves a Vice Chair of the national Mayo Clinic Cancer Center Practice Committee,
overseeing cancer care delivery at all of Mayo’s national sites, and Medical Director
Particle Therapy at Mayo Clinic Florida. He previously served as Vice Chairman of the
Board of Trustees of the Mayo Clinic Health System – Albert Lea and Austin. Professor
Robert Miller is a physician-executive at the Mayo Clinic, where he has been employed
for the last 25 years. He is the author of over 170 peer-reviewed papers. Robert has
successfully led a series of national, NIH funded Phase III clinical trials searching for
new pharmaceutical solutions to reduce symptoms of cancer therapy. Robert began his
scientific career as a medical physicist at the University of Kentucky, before going on
to graduate from medical school at the University of Kentucky. Robert also received
an MBA from Oxford University. Robert has been appointed Medical Director of
the Maryland Proton Treatment Center and Professor at the University of Maryland
beginning April 1, 2019.
Clifford M Gross, PHD
Chairman and CEO
M J Malcolm Groat
Finance Director
R W “Bill” Payne
Non Executive Director
Robert Miller, MD
Non Executive Director
22
OFFICERS AND
PROFESSIONAL ADVISERS
Registered Office
12 New Fetter Lane
London
EC4A 1JP
Auditor
H W Fisher & Company
11 – 15 William Road
London NW1 3ER
Banks
HSBC plc
Canada Place
Canary Wharf
London
E14 5AH
The Toronto-Dominion Bank
12620 Biscayne Blvd
North Miami
FL 33181
USA
Solicitors
Bird & Bird LLP
12 New Fetter Lane
London EC4A 1JP
Nominated Adviser and Joint-
Broker
finnCap Ltd
60 New Broad Street
London EC2M 1JJ
Joint-Broker
Novum Securities Limited
8-10 Grosvenor Gardens
Belgravia
London SW1W 0DH
Investor Relations
Yellow Jersey ltd
Top floor, 70-71 Wells St
London W1T 3QE
www.tekcapital.com
DIRECTORS’ REPORT
FOR THE YEAR-ENDED
30 NOVEMBER 2018
Directors
The following Directors held office during the period, and to the date of this report.
Clifford M Gross, PhD
M J Malcolm Groat
R W “Bill” Payne
Robert Miller, MD
The Group has chosen to set out in the groups strategic report information required to be contained in the
directors’ report. It has done so in respect of future developments and research and development activities.
Statement of Directors’ responsibilities
The Directors are responsible for preparing the annual report and the financial statements in accordance with
applicable law and regulations. Company law requires the Directors to prepare financial statements for each
financial year. Under that law the Directors have prepared the Group and parent company financial statements
in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. Under
company law the Directors must not approve the financial statements unless they are satisfied that they give a true
and fair view of the state of affairs of the Group and the Company and of the profit or loss of the Group for that
period. In preparing these financial statements, the Directors are required to:
• select suitable accounting policies and then apply them consistently;
• make judgements and accounting estimates that are reasonable and prudent;
• state whether applicable IFRSs as adopted by the European Union have been followed,
subject to any material departures disclosed and explained in the financial statements; and
• prepare the financial statements on the going concern basis unless it is inappropriate to
presume that the Group and the Company will continue in business.
The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the
Group’s transactions and disclose with reasonable accuracy at any time the financial position of the Company and
the Group to enable them to ensure that the financial statements comply with the Companies Act 2006. They are
also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps
for the prevention and detection of fraud and other irregularities.
Each of the current Directors, whose names are listed in the Directors’ report on this page of the financial statements
confirm that, to the best of each person’s knowledge and belief:
• the financial statements, prepared in accordance with IFRS as adopted by the European Union,
give a true and fair view of the assets, liabilities, financial position and profit (or Loss) of the Group and Company;
and
• the chairman’s statement contained in the annual financial statements includes a fair review of the
development and performance of the business and the position of the Group and Company, together with a
description of the principal risks and uncertainties that they face.
The Directors are responsible for the maintenance and integrity of the corporate and financial information included
on the Group’s website www.tekcapital.com. Legislation in the United Kingdom governing the preparation and
dissemination of financial statements may differ from legislation in other jurisdictions.
Going concern
The Group meets its day to day working capital requirements through its service offerings, bank facilities and
monies raised in follow-on offerings. The Group’s forecasts and projections indicate that the Group has sufficient
cash reserves to operate within the level of its current facilities. Whilst it is the Group’s intention to rely on the
available cash reserves, future income generated from its growing service offerings and reductions in its cost base,
a negative variance in the forecasts and projections would make the Group’s ability to continue as as going concern
dependent on an additional fund raise. If the Group’s forecasts are not achieved, the Directors would seek to raise
the additional funds through equity issues. After making enquires, the Directors have a reasonable expectation that
the Group has adequate resources to continue in operational existence for the foreseeable future. The Company
therefore contnues to adopt the going concern basis in preparing both its consolidated financial statements and
for its own financial statements.
23
DIRECTORS’ REPORT FOR THE YEAR ENDED 30 NOVEMBER 2018
Dividends
No dividend was paid or was proposed during the year ended 30 November 2018.
Audit Committee
The Board operates an Audit Committee, chaired by Bill Payne. This Committee carries out duties as set out in the AIM Admission Document,
supervising the financial and reporting arrangements of the Group. During the period, no issues arose that the Directors consider appropriate to
disclose in their Report.
Remuneration Committee
The Board has delegated to its Remuneration Committee, chaired by Dr Robert Miller, certain responsibilities in respect of the remuneration of
senior executives. During the period, no issues arose that the Directors consider appropriate to disclose in their Report.
Directors’ Emoluments
The Group did not make any contributions to a pension scheme in the year ended 30 November 2018 (2017: Nil).
Directors’ beneficial interests in shares
The details of the options held by each director at 30 November 2018 are as follows:
24
www.tekcapital.com DIRECTORS’ REPORT FOR THE YEAR ENDED 30 NOVEMBER 2018
* The options vest in three equal annual instalments from the date of grant and there is a special condition which means the options will vest
when the closing price for a share has been traded at more than one pound sterling for ten consecutive trading days.
Principal Risks and Uncertainties
The specific financial risks are discussed in the notes to the financial statements. Other risks are as follows:
- the principal financial risks of the business relate to the value of the Group’s portfolio companies. We believe that the fair value of each
portfolio company is a time dependent valuation that may be impaired if the business does not achieve it milestones, growth trajectory,
product development, capital raises or other key performance metrics. Individually and as a group our portfolio companies have a material
impact on our financial performance. This risk of individual portfolio company negative performance may be ameliorated as our portfolio
becomes more diverse and increases in value.
- the principal operational risk of the business is management’s ability to assist our portfolio companies in achieving their goals and ultimate
exits whilst increasing our service revenues.
- the Group is dependent on its executive team and directors for its operations and ultimate success and there can be no assurance that it
will be able to retain the services of these key personnel in the future.
- a Brexit also presents potential risks for our business in as much as it may negatively affect investor sentiment towards early stage busi-
nesses. Further, until the Group covers all of its operating costs from service revenue and or exits it will seek to raise additional capital to fund
operations and follow-on investments in portfolio companies.
Post Balance Sheet Events
For further details, please refer to note 26 in the notes to the accounts.
Independent auditors
H. W. Fisher & Company were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, a resolu-
tion proposing that they be re-appointed will be put at a General Meeting.
Statement of disclosure of information to auditors
Each of the persons who was a Director at the date of approval of this report confirms that:
• so far as the Director is aware, there is no relevant audit information of which the Company’s auditor is unaware; and
• the Director has taken all the steps that he ought to have taken as a Director in order to make himself aware of any relevant audit informa-
tion and to establish that the Company’s auditor is aware of that information.
This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.
By order of the Board of Directors and signed on behalf of the Board
M J Malcolm Groat
Director
13 March 2018
25
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
TEKCAPITAL PLC
Opinion
We have audited the financial statements of Tekcapital Plc (the ‘parent company’) and its subsidiaries (the ‘Group’) for the year ended 30
November 2018 which comprise:
•
•
•
•
•
the consolidated Statement of Comprehensive Income;
the consolidated and parent company Statements of Financial Position,
the consolidated and parent company Statement of Changes in Equity;
the consolidated Statement of Cash Flows;
the related notes to the consolidated and parent company financial statements including a summary of significant accounting
policies.
The financial reporting framework that has been applied in the preparation of the Group financial statements is applicable law and Interna-
tional Financial Reporting Standards (‘IFRSs’) as adopted by the European Union. The financial reporting framework that has been applied in
the preparation of the parent company financial statements is applicable law and United Kingdom Accounting Standards, including FRS101
“Reduced Disclosure Framework” (United Kingdom Generally Accepted Accounting Practice).
In our opinion:
•
•
•
•
the financial statements give a true and fair view of the state of the Group’s and of the parent company’s affairs as at 30 November
2018 and of the Group’s profit for the year then ended;
the Group’s financial statements have been properly prepared in accordance with International Financial Reporting Standards
(‘IFRSs’) as adopted by the European Union;
the parent company financial statements have been prepared in accordance with United Kingdom Generally Accepted Accounting
Practice; and
the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities
under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report.
We are independent of the Group and parent company in accordance with the ethical requirements that are relevant to our audit of the
financial statements in the UK, including the FRC’s Ethical Standard as applied to listed entities, and we have fulfilled our other ethical respon-
sibilities in accordance with these requirements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
The impact of uncertainties due to Britain exiting the European Union on our audit
Uncertainties related to the effects of Brexit are relevant to understanding our audit of the financial statements. All audits assess and
challenge the reasonableness of estimates made by the directors, such as recoverability of investments, intangible assets and related
disclosures and the appropriateness of the going concern basis of preparation of the financial statements. All of these depend on
assessments of the future economic environment and the Group’s future prospects and performance.
Brexit is a significant area of uncertainty, in our opinion the key impact of Brexit upon the Group is likely, but not limited to the impact on
the fair value assessments, the foreign exchange risk exposure and the going concern which includes the Group’s ability to continue to raise
funds. We as auditors are not able to, nor should we be expected to predict the impact the future uncertainties will have on the Company
and the Group.
26
www.tekcapital.com
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
Conclusions related to going concern
We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:
•
•
the directors’ use of the going concern basis of accounting in the preparation of the financial statements is not appropriate;
or
the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant
doubt about the company’s ability to continue to adopt the going concern basis of accounting for a period of at least
twelve months from the date when the financial statements are authorised for issue.
Summary of our audit approach
Context
The parent company continued to recognise Tekcapital Europe Limited and Tekcapital LLC as subsidiaries and has continued to
consolidate both entities in the preparing the consolidated financial statements. The other subsidiaries continue to be treated as
portfolio investments under IFRS 10, investment entities.
Key audit matters
Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial
statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to
fraud) we identified, including those which had the greatest effect on: the overall audit strategy, the allocation of resources in the
audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial
statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
The key audit matters that we identified in the current year were:
•
•
•
•
•
Valuation of unquoted equity investments.
Going Concern, based on the Group’s ability to raise funds.
Revenue recognition and accuracy of cut off in the period;
Management override of controls;
Reliance on Expert
Our application of materiality
The materiality that we used for the consolidated financial statements was $200,000. We determined materiality using 1% of gross
assets.
The materiality that we used for the parent company’s financial statements was $60,000. We determined materiality using 1% of gross
assets.
An overview of the scope of the audit
27
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
Area of focus
How our audit addressed the area of focus
Valuation of unquoted equity
investments
83% of the Group’s total assets (by value)
is held in investments where no quoted
market price is available. Unquoted
Investments are measured at fair value,
unlisted investments determinable
prices.
The valuation techniques used fall
under level 2 and level 3 of the fair value
hierarchy.
This is a key area of estimation and we
therefore considered this to be an area of
significant audit risk and focus.
The Group engages an independent
expert valuer for the purpose of
determining the fair value of the assets
held within the investments to help
mitigate this risk.
Our audit work included, but was not restricted to the following:
• We reviewed the appropriateness of the Group’s disclosures within the financial statements in relation to
valuation methodology, key valuation inputs and valuation uncertainty.
• We addressed the competency, qualifications, independence and objectivity of the valuer as documented in
the key area of focus below.
• We re-performed the calculations and in instances where the reliance on the expert was not considered
sufficient we assessed the reasonableness of inputs used in the valuation and performed benchmarking.
• We performed a review of the valuations sensitivity to the discount rates and other key areas of estimation
and reviewed the sensitivity disclosure calculations.
• We agreed the inputs in the discounted cash flows used for the royalty relief valuations and the e-shop
valuation to the independent reports.
• We considered the impact of deferred tax on the fair value gains recognised on the IP held in the investments
and considered these amounts within the valuations.
• For items which were material but were not fair valued on the investment company’s balance sheet we
vouched to appropriate audit evidence such as bank statements to support the cash balances or the Crypto
wallets to support the crypto currency.
• Reconciliation of the fair value movements to the financial statements.
• We reviewed the underlying licence agreements on the patents to ensure the ownership / exclusivity.
• We assessed the critical accounting judgement disclosure at note 4 to the financial statements in respect of
the directors’ determination of the Group as an investment entity
Based on our audit work detailed above, we confirm that we have nothing material to report, and or draw
attention to in respect of these matters.
Going concern
Our audit work included, but was not restricted to the following:
The parent company and subsidiaries are
not currently profit generating and are
reliant upon their ability to raise funds.
The operating profit is a result of the fair
value gains on the investments which is
unrealised.
• We have reviewed the directors’ statement regarding the appropriateness of the going concern basis of
accounting contained within note 2.2.1 to the financial statements.
• We have reviewed the available consolidated financial forecasts of the group in line with the assertions
provided throughout the audit to assess their reasonableness.
• We have applied sensitivities to the consolidated financial forecasts to review the impact in line with the
wording included within the going concern policy and agreed that should there be a negative variance in the
forecasts projected the Group will be reliant upon a future fundraise.
• We have reviewed the post year end management accounts
• We have reviewed the announcements and considered if any items will have a financial impact affecting the
going concern
• We have reviewed the disclosures at note 3 that describe the financial risks and explain how they are being
managed or mitigated.
Based on our audit work detailed above, we confirm that we have nothing material to report, and or draw
attention to in respect of these matters. We agreed the director’s disclosure of the going concern as disclosed
within note 2.1.1 of the financial statements. We did not identify any such material uncertainties, However,
because not all future events or conditions can be predicted, this statement is not a guarantee as to the
Company’s ability to continue as a going concern.
28
www.tekcapital.com INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
Area of focus
How our audit addressed the area of focus
Assessment of revenue recognition
Our audit work included, but was not restricted to the following:
There is a presumed risk of misstatement
arising from lack of completeness or
inaccurate cut-off relating to revenues.
Revenue also includes a significant
amount of unrealised income from
investments held at fair value through
profit and loss which is material to the
financial statements
• We evaluated the sales controls system in place to determine the controls surrounding the income.
• We checked a sample of the sales agreements and contracts through to the income recognised in the
accounts and invoices.
• We also completed checks on deferred and accrued income, no material misstatements were identified in
respect of the deferred income not recognised.
• We reviewed the revenue recognition accounting policy at note 2.21 of the financial statements to ensure
the application was consistent.
• We assessed the accounting policy for the fair value gains / losses on the investments measured at fair value
to check that gains had been accounted for in accordance with the stated accounting policy.
Based on our audit work detailed above, we confirm that we have nothing material to report, and or draw
attention to in respect of these matters
Management override of controls
Our audit work included but was not restricted to the following:
Management is in a unique position to
override controls that otherwise appear
to be operating effectively.
• We undertook testing on the companies controls, we extended our audit testing to perform enhanced
management override procedures.
• We undertook a review to gain an understanding of the overall governance and oversight process
surrounding management’s review of the financial statements.
• We examined the significant accounting estimates and judgements relevant to the financial statements for
evidence of bias by the directors.
• We reviewed the financial statements and considered whether the accounting policies are appropriate and
have been applied consistently.
• We undertook a review of the journals posted through the nominal ledger for significant and unusual
transactions and investigated them, reviewing and confirming the company valuation of journal entry
postings.
Based on our audit work detailed above, we confirm that we have nothing material to report, and or draw
attention to in respect of these matters.
29
INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
Other information
The directors are responsible for the other information. The other information comprises the information included in the annual report, other
than the financial statements and our auditor’s report thereon.
Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our
report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether
the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to
be materially misstated.
If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material
misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we
conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this
regard.
Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
•
prepared is consistent with the financial statements; and
the information given in the strategic report and the directors’ report for the financial year for which the financial statements are
•
the strategic report and the directors’ report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not
identified material misstatements in the strategic report or the directors’ report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in
our opinion:
•
from branches not visited by us; or
adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received
•
•
the parent company financial statements are not in agreement with the accounting records and returns; or
we have not received all the information and explanations we require for our audit.
Responsibilities of directors
As explained more fully in the Directors’ responsibilities statement, the Directors are responsible for the preparation of the financial
statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to
enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the Directors are responsible for assessing the Group’s and the parent company’s ability to continue
as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the
Directors either intend to liquidate the Group or the parent company or to cease operations, or have no realistic alternative but to do so.
30
www.tekcapital.com INDEPENDENT AUDITOR’S REPORT TO THE MEMBERS OF
TEKCAPITAL PLC
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material
misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high
level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement
when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could
reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s
website at: http://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report
Use of our audit report
This report is made solely to the parent company’s members, as a body, in accordance with chapter 3 of Part 16 of the Companies Act
2006. Our audit work has been undertaken so that we might state to the parent company’s members those matters we are required to
state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the parent company and the parent company’s members as a body, for our audit work, for this report,
or for the opinions we have formed.
Gary Miller (Senior Statutory Auditor)
For and on behalf of H W Fisher & Company
Chartered Accountants
Statutory Auditor
Acre House
11/15 William Road
London
NW1 3ER
United Kingdom
Date: 13 March 2019
31
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE
YEAR ENDED 30 NOVEMBER 2018
The Group has used the exemption under S408 CA 2006 not to disclose the Company income statement.
Items in the statement above are disclosed net of tax.
The notes on pages 38 to 67 are an integral part of these consolidated financial statements.
32
www.tekcapital.com CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT 30 NOVEMBER 2018
The notes on pages 38 to 67 are an integral part of these financial statements.
The financial statements on pages 32 to 67 were authorised for issue by the Board of Directors on 13 March 2019 and were signed on its
behalf.
M J Malcolm Groat
Director
Tekcapital PLC
registered number 08873361
Dr Clifford M Gross
Chairman and CEO
33
COMPANY STATEMENT OF FINANCIAL POSITION
COMPANY STATEMENT OF FINANCIAL POSITION
AT 30 NOVEMBER 2018
AT 30 NOVEMBER 2018
The notes on pages 38 to 67 are an integral part of these financial statements.
The financial statements on pages 32 to 67 were authorised for issue by the Board of Directors on 13 March 2019 and were signed on its
behalf.
The Company’s loss before tax for the year ended 30 November 2018 was $920,213.
Dr Clifford M Gross
Chairman and CEO
M J Malcolm Groat
Director
Tekcapital PLC
registered number 08873361
34
www.tekcapital.com
CONSOLIDATED STATEMENT OF CHANGES IN THE EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2018
Share premium - amount subscribed for share capital in excess of nominal value, net of directly attributable costs.
Translation reserve - amount subscribed for foreign exchange differences recognized in Other Comprehensive Income
Merger reserve - amount subscribed for share capital in excess of nominal value in relation to the qualifying acquisition of subsidiary undertakings.
Retained earnings - cumulative net gains and losses recognised in the consolidated statement of comprehensive income
The notes on pages 38 to 67 are an integral part of these financial statements.
35
COMPANY STATEMENT OF CHANGES IN THE EQUITY
FOR THE YEAR ENDED 30 NOVEMBER 2018
Share premium – amount subscribed for share capital in excess of nominal value, net of directly attributable issue costs.
Translation reserve – amount subscribed for foreign exchange differences recognized in Other Comprehensive income.
Retained earnings – cumulative net gains and losses recognized in the consolidated financial statements of comprehensive income
The notes on pages 38 to 67 are an integral part of these financial statements.
36
www.tekcapital.com CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEAR ENDED 30 NOVEMBER 2018
Please note approximately $0.8m of cash used was attributed to Belluscura plc through deconsolidation date of May 1, 2017
* Non-cash investing activities: included in purchases of financial assets at fair value through profit and loss are non-cash additions in
respect of the conversion of US$0.56m loan receivable from Belluscura Limited into equity classified as Additions in Note 11.
37
NOTES TO THE FINANCIAL STATEMENTS
1.
General Information
Tekcapital PLC is a company incorporated in England and Wales and domiciled in the UK. The address of the registered office is detailed on
page 1 of these financial statements. The Company is a public limited company, which listed on the AIM market of the London Stock
Exchange in 2014. The principal activity of the parent company is that of an investment entity and that of the Group is to provide
universities and corporate clients with a wide range of technology transfer services. The Group and the parent company also acquire
exclusive licenses for disruptive technologies it has acquired for its own portfolio, for subsequent commercialisation.
The principal accounting policies applied in the preparation of these consolidated financial statements and parent company financial
statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
2.
2.1
Accounting policies
Statement of compliance
The consolidated financial statements of Tekcapital PLC Group have been prepared in accordance with International Financial Reporting
Standards (IFRS) and IFRS Interpretations Committee (IFRS IC) as adopted by the European Union and the Companies Act 2006 applicable
to companies reporting under IFRS. The consolidated financial statements have been prepared under the historical cost convention. The
consolidated financial statements comprise the financial statements of Tekcapital plc and its subsidiaries, Tekcapital Europe Ltd and
Tekcapital LLC.
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It requires
management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of
judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in
note 4.
The financial statements of the parent company have been prepared in accordance with Financial Reporting Standard 101 “Reduced
disclosure framework” (‘FRS 101’). The company will continue to prepare its financial statements in accordance with FRS101 on an ongoing
basis until such time as it notifies shareholders of any change to its chosen accounting framework.
The Company financial statements have been prepared using the historical cost convention except where other measurement basis are
required to be applied and in accordance with IFRS under FRS 101. In accordance with FRS101, the company has taken advantage of the
following exemptions:
• IAS 7, ‘Statement of Cash Flows’
• Requirements of IAS 24, ‘Related Party Disclosures’ to disclose related party transactions entered into between two or more members
of a group.
2.1.1
Going concern
The Group meets its day to day working capital requirements through its service offerings, bank facilities and monies raised in follow-on
offerings. The Group’s forecasts and projections indicate that the Group has sufficient cash reserves to operate within the level of its current
facilities. Whilst it is the Group’s intention to rely on the available cash reserves, future income generated from its growing service offerings
and reductions in its cost base, a negative variance in the forecasts and projections would make the Group’s ability to continue as a going
concern dependent on an additional fund raise. If the Group’s forecasts are not achieved, the Directors would seek to raise the additional
funds through equity issues. After making enquiries, the Directors have a reasonable expectation that the Group has adequate resources to
continue in operational existence for the foreseeable future.
The Company therefore continues to adopt the going concern basis in preparing both its consolidated financial statements and for its own
financial statements.
2.1.2
Changes in accounting policy and disclosures
New standards and interpretations not yet adopted by the Group
The following standards became effective during the year ended 30 November 2018: IAS 7, IAS 12 and IFRS 12.
38
www.tekcapital.com
A number of new standards and amendments to standards and interpretations are effective for the periods after 30 November 2018, and
have not been applied in preparing these consolidated financial statements:
Amendments to IFRS 2 “classification and Measurement of Share-based Payment Transactions”
The amendments break down into three distinct areas:
-
-
-
Classification of share-based payments that have a net settlement feature within the framework of an equity-settled plan: none
applicable to the Group
Accounting for modifications that change the classification of payments from cash-settled to equity-settled: no such
modifications applicable to the Group
The effects of vesting/non-vesting conditions on cash-settled share-based payments: no cash-settled share-based payments
applicable.
Amendments to IFRS 4 “Applying IAS 39 Financial Instruments with IFRS 4 insurance contracts”
No IFRS 4 insurance contracts are applicable to the Group. As such, no material impact on the financial statements was determined.
IFRS 9 “Financial Instruments”
IFRS 9 “Financial Instruments” was issued in July 2014 to replace IAS 39 “Financial Instruments: Recognition and Measurement” and has been
endorsed by the EU. The standard is effective for accounting periods beginning on or after 1 January 2018. The most significant change
resulting from IFRS 9 is how banks account for loan losses, and the standard does not introduce significant changes to Group’s accounting
policies as compared to IAS 39. All assets within the scope of IFRS 9 are measured at either:
-
-
-
Amortized cost
Fair value through other comprehensive income
Fair value through profit and loss.
The Group measures its financial assets primarily at fair value through profit and loss as documented in Note 2.9 and the standard does not
introduce material changes to measurement of those. As such, no material impact on the financial statements was determined.
IFRS 15 Revenue from contracts with customers
IFRS 15 was issued in September 2015 and is effective for accounting periods beginning on or after 1 January 2018. The review of IFRS 15
is ongoing and the Directors have undertaken an assessment of the impact of the standard on the Group based on the standard’s latest
authoritative guidance. The Group will adopt IFRS 15 on 1 December 2018 and will restate any comparative figures for the year ended 30
November 2018 where relevant. The directors are finalising the assessments of the review and expect these to show that there will be no
material impact on the way revenues are recognised across the Group. While the assessment is ongoing, Directors believe the impact will
be limited considering the fact overall materiality of Group’s service revenue and the fact that Group’s material revenue, Unrealised profit/
loss on revaluation of investments, falls under IFRS 9 that is excluded from the scope of IFRS 15. The ongoing assessment incorporates the
five-step process:
-
-
-
-
-
Identification of contract
Determination of performance obligations
Determination of transaction price
Allocation of price to performance obligations
Recognition of revenue.
IFRS 16 Leases
IFRS 16 was issued in January 2016 and is effective for accounting periods beginning on or after 1 January 2019. IFRS 16’s new requirement
to recognise a right-of-use asset and a related liability is expected to have a significant impact on the amounts recognised in the Group’s
consolidated financial statements and the Group is currently assessing its potential impact. This will have an impact on Group’s
39
NOTES TO THE FINANCIAL STATEMENTS
NOTES TO THE FINANCIAL STATEMENTS
consolidated financial statements because operating lease as disclosed in Note 23 will no longer be treated as off balance sheets
commitments.
No other issued but not endorsed amendments to IFRS will have a material impact on the Group’s financial statements once they become
endorsed and effective.
2.2
Business combinations
Tekcapital PLC was incorporated on 3 February 2014 and on 18 February 2014 entered into an agreement to acquire the issued share capital
of Tekcapital Europe Limited by way of share issue. On 19 February 2014 it acquired the issued share capital of Tekcapital LLC also by share
issue. This has been accounted for as a common control transaction under IFRS 3 using the pooling of interest method by using the
nominal value of shares exchanged in the business combination and no fair value adjustment.
The consolidated financial statements comprise the financial statements of Tekcapital PLC and all subsidiaries controlled by it.
Subsidiaries are entities that are controlled by the Group. Control is achieved when the Group has the power to govern the financial and
operating policies of an entity so as to obtain economic benefit from its activities. Inter-company transactions, balances and unrealised
gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated when necessary amounts reported
by subsidiaries have been adjusted to conform to the Group’s accounting policies.
2.3
Foreign currencies
(a) Functional and presentation currency
These consolidated financial statements are presented in US Dollars which is the presentation currency of the Group. This is because the
majority of the Group’s transactions are undertaken in US Dollars. Each subsidiary within the Group has its own functional currency which
is dependent on the primary economic environment in which that subsidiary operates. Effective 1 December 2014 Tekcapital PLC and
Tekcapital Europe Limited changed their functional currency to UK Sterling. This is because, the primary economic activity of these entities
is undertaken in the UK.
(b) Transactions and balances
Foreign currency transactions are translated into functional currency using the exchange rates prevailing at the dates of the transactions
or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from
the translation at the year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the
income statement. Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the income
statement within ‘finance income or costs’.
(c) Group companies
The results and financial position of all Group entities (none of which has the currency of a hyper-inflationary economy) that have a
functional currency different from the presentation currency are translated into the presentation currency as follows:
(i)
(ii)
(iii)
assets and liabilities for each balance sheet presented are translated at the closing exchange rates at the date of that balance
sheet.
income and expense for each income statement are translated at the average rates of exchange during the period (unless this
average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case
income and expenses are translated at the rate on the dates of the transactions)
all resulting exchange differences are recognised in other comprehensive income.
2.4
Investment in subsidiaries
Investments in subsidiaries are recognised initially at cost. The cost of the investment includes transactions costs. The carrying amounts are
reviewed at each reporting dated to determine whether there is any indication of impairment. Following the adoption of the change in the
accounting for its investments described in Note 2.1.2 for 2017 financial statements, Tekcapital transferred its investments in these
40
www.tekcapital.com
companies from investment in subsidiaries to investments held at fair value through the profit and loss for Belluscura and its other
Intellectual Property portfolio investments effective 1 May 2017. As a result of this adoption and deconsolidation of previously consolidated
subsidiaries in comparable period ended 30 November 2017, the Group recognized a gain of $226,656 in the year ended 30 November
2017. Directors’ judgment was exercised in determination that the Group meets the following criteria and should be recognized as an
investment entity under IFRS 10 par. 27:
• Obtains funds from one or more investors for the purpose of providing clients with investment management services
• Commits to its investors that its business purpose is to invest funds solely for return from capital appreciation, investment income or
both
• Measures and evaluate the performance of substantially all of its investments on a fair value basis.
Tekcapital’s IP search and technology transfer investment services represent investment advisory services, and therefore Tekcapital Europe
Limited and Tekcapital LLC continue to be treated as subsidiaries and are consolidated in the Group financial statements. These services
may be provided to investors, clients and third parties. The Board considers that the criteria are met in the group’s current circumstances.
In 2017, Tekcapital has refined its business purpose to that of providing intellectual property investment services and advice to create
market value. This refined focus has become one of creating value primarily through out-licensing of intellectual properties and in some
cases from the monetisation of portfolio company investments primarily through out-licensing and also through trade sales or Initial Public
Offerings, when appropriate. The Board envisages that Tekcapital’s shareholder returns will derive primarily from mid to long-term capital
appreciation of a portion of its intellectual property investments, as well as from providing IP investment services to clients. Consequently,
the Group’s portfolio companies are measured at fair value in accordance with IAS 39 as disclosed in Note 2.9.
2.5
Non-controlling interests
Losses applicable to non-controlling interests in a subsidiary are allocated to the non-controlling interests, even if doing so causes the
non-controlling interests to have a deficit balance. Adjustments to non-controlling interests arising from transactions that do not involve
the loss of control are based on a proportionate amount of the net assets of the subsidiary. Upon the loss of control the assets and liabilities
of the subsidiary, any non-controlling interests and other components of equity related to the subsidiary are derecognised. Any resulting
gain or loss is recognised in the profit and loss.
2.6
Property, plant and equipment
Property, plant and equipment is stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly
attributable to the acquisition of the items. Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset,
as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the
item can be measured reliably. All other repairs and maintenance are charged to the income statement during the financial period in which
they are incurred. Depreciation of assets are calculated to write off the cost less the estimated residual value of tangible fixed assets by
equal instalments over the estimated useful economic lives as follows:
Furniture
Computer equipment
Leasehold improvements
3 years
3 years
5 years
The assets’ residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. The asset’s
carrying amount is written down immediately to its recoverable amount if the assets carrying value is greater than its estimated
recoverable amount. Gains and losses on disposals are determined by comparing proceeds with the carrying amount and are recognised
within ‘Other gains / (losses) – net’ in the income statement. When re-valued assets are sold, the amounts included in other reserves are
transferred to retained earnings.
2.7
Intangible assets
(a) Invention Evaluator
This is an intangible asset and a piece of computer software acquired for use by one of the subsidiaries of the Group and is shown at
original cost of purchase less impairment losses.
41
NOTES TO THE FINANCIAL STATEMENTS
Under IAS38, this asset is regarded by the Directors as being an intangible asset with an indefinite useful life. The Directors believe that the
asset is unique in that no competitor offering currently exists, the service appeals globally to many types of clients including Fortune 100
companies, there is no expectation of obsolescence in the foreseeable future, and the service provided by the asset generates sufficient
ongoing revenue streams.
Consequently, no write down in the value of this asset either by way of amortisation or impairment has occurred in this financial year. In the
Directors’ opinion this asset has an indefinite useful life.
(b) Computer software and website development
Costs associated with maintaining computer software programmes and the Company website are recognised as an expense as incurred.
Development costs that are directly attributable to the design and testing of identifiable and unique software products controlled by the
Group are recognised as intangible assets when the following criteria are met:
(i)
(ii)
(iii)
(iv)
(v)
it is technically feasible to complete the software product so that it will be available for use;
management intends to complete the software product and use or sell it;
there is an ability to use or sell the software product;
it can be demonstrated how the software product will generate probable future economic benefits;
adequate technical, financial and other resources to complete the development and to use or sell the software product are
available; and
the expenditure attributable to the software product during its development can be reliably measured.
(vi)
Computer software development costs recognised as assets are amortised over their estimated useful lives, which do not exceed four years.
(c) Licences
Costs associated with the acquisition of Licences for technologies with the express purpose of developing them further for a commercial
market are recognised as an intangible asset when they meet the criteria for capitalisation. That is, they are separately identifiable and
measurable and it is probable that economic benefit will flow to the entity.
Further development costs attributable to the Licenced technology and recognised as an intangible asset when the following criteria are
met:
it is technically feasible to complete the technology for commercialisation so that it will be available for use;
management intends to complete the technology and use or sell it;
there is an ability to use or sell the technology;
it can be demonstrated how the technology will generate probable future economic benefits;
adequate technical, financial and other resources to complete the development and to use or sell the technology are available;
(i)
(ii)
(iii)
(iv)
(v)
and
(vi)
Licences and their associated development costs are amortised over the life of the license or the underlying patents, whichever is shorter.
the expenditure attributable to the technology during its development can be reliable measured.
(d) Vortechs Group
This is an intangible asset acquired for use by one of the subsidiaries of the Group and is valued at original cost of purchase.
Under IAS38, the Group’s Vortechs Group asset is regarded by the Directors as being an intangible asset with an indefinite useful life. The
Directors believe that this asset is unique as it operates in a niche market, it generates an ongoing revenue stream, and there is no
expectation of obsolescence. This asset meets the requirements of IAS38 as it is separately identifiable, controlled by the Group, the cost
can be measured reliably, and as a result of owning this asset future economic benefits in the form of service revenue are generated for the
Group.
In the opinion of the Directors this asset has an indefinite useful life and there has been no amortisation or impairment provided in the
current year.
42
www.tekcapital.com
2.8
Impairment of non-financial assets
Intangible assets that have an indefinite useful life or intangible assets not ready to use are not subject to amortisation and are tested
annually for impairment. Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset’s carrying
value exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use.
For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows,
(CGUs). Prior impairments of non-financial assets (other than goodwill) are reviewed for possible reversal at each reporting date.
2.9
Financial instruments
2.9.1
Classification
The Company classifies its financial assets depending on the purpose for which the asset was acquired. Management determines the
classification of its financial assets at initial recognition.
During the financial year the Group held investments into Lucyd Ltd, Belluscura plc and other portfolio companies classified as equity
investments. They are included in current assets and are measured at fair value through profit and loss in accordance with IAS 39.
The Company also has loans, convertible loan notes and receivables that are non-derivative financial assets with fixed or determinable
payments that are not quoted in an active market. They are included in current assets, except for maturities that are greater than 12 months
after the end of the reporting year. These are classified as non-current assets. The Group’s loans and receivables comprise ‘trade and other
receivables’ in the balance sheet. The Group also has cash and cash equivalents.
All short term financial liabilities are measured at cost, the Group does not hold any long term financial liabilities.
2.9.2
Recognition and measurement
The Company’s investments into the portfolio companies are recognised on the acquisition or formation date and measured at fair value
through profit or loss in accordance with IAS 39.
Loans and receivables are recognised on the trade date in which the transaction took place and are recognised at their fair value (which
equates to cost) with transaction costs expensed in the income statement. Financial assets are derecognised when the rights to receive
cash flows from the loans or receivables have been collected, expired or transferred and the Group has subsequently transferred
substantially all risks and rewards of ownership. Short term financial liabilities are initially measured at fair value and subsequently
measured at amortised cost using the effective interest rate method.
2.9.3
Fair value
Financial instruments are measured at fair value including investments in portfolio companies, cash and cash equivalents, trade and other
receivables, trade and other payables, and borrowings. This measurement policy does not apply to subsequent measurement at amortised
cost of short term financial liabilities and trade receivables.
The Group measures portfolio companies using valuation techniques appropriate in the circumstances and for which sufficient data are
available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs. Our
newly adopted fair value valuation policy is as follows:
• The fair value of new portfolio companies is estimated at the cost of the acquired IP or equity plus associated expenses to
facilitate the acquisition.
• Existing portfolio companies are valued as follows:
- If a market transaction such as third-party funding has occurred during the past 18 months we will value our ownership in the
portfolio company at this observed valuation, taking account of any observed material changes during the period.
- In the absence of a recent market transaction, fair value will be estimated by alternative methods and where appropriate by an
external, qualified valuation expert. The valuation technique used fall under Level 2 – Observable techniques other than quoted
prices and Level 3 – other techniques as defined by IFRS 13.
43
NOTES TO THE FINANCIAL STATEMENTS
prices and Level 3 - other techniques as defined by IFRS 13.
Due to their short-term nature, the carrying value of cash and cash equivalents, trade and other receivables, and trade and other payables
approximate their fair value. The fair value of borrowings equals their carrying amounts, as the impact of discounts is not significant.
2.10
Offsetting financial instruments
Financial assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset
the recognised amounts and there is the intention to settle on a net basis or realise the asset and settle the liability simultaneously.
2.11
Impairment of financial assets
The Group assesses at the end of each reporting year whether there is objective evidence that a financial asset or group of financial assets
is impaired. A financial asset or group of financial assets is impaired and impairment losses are incurred only if there is objective evidence
of impairment as a result of one or more events that have occurred after the initial recognition of the asset (a ‘loss event’) and the loss event
(or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.
Evidence of impairment may include indications that the debtors or a group of debtors is experiencing significant financial difficulty,
default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganisation,
and where observable data indicate that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or
economic conditions that correlate with defaults.
For the loans and receivables category, the amount of the loss is measured as the difference between the assets carrying amount and the
present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset’s
original effective interest rate. The carrying amount of the asset is reduced and the amount of the loss is recognised in the consolidated
income statement. If a loan or held-to maturity investment has a variable interest rate, the discount rate for measuring any impairment loss
is the current effective interest rate determined under the contract. As a practical expedient, the Group may measure impairment on the
basis of an instrument’s fair value using an observable market price.
If, in a subsequent year, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring
after the impairment was recognised (such as the improvement in the debtor’s credit rating), the reversal of the previously recognised
impairment loss is recognised in the consolidated income statement.
2.12
Trade receivables
Trade receivables are amounts due from customers for the provision of services performed in the ordinary course of business. Collection is
normally expected within three months or less (in the normal operating cycle of the business) and is classified as current assets. In the rare
circumstances that they exceed a period of greater than one year they are presented as non-current assets. In some instances, the Group
accepts convertible loan notes for trade debts these are held separately on the statement of financial position until maturity or disposal on
the open market. Any value received which is greater or less than the value of the original debt is taken to the consolidated statement of
comprehensive income.
Trade receivables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method,
less any provision for impairment.
2.13
Cash and cash equivalents
In the consolidated statement of cash flows, cash and cash equivalents includes cash in hand, deposits held at call with other banks, other
short term highly liquid investments with maturities of three months or less and bank overdrafts. In the consolidated statement of financial
position, bank overdrafts are shown within borrowings in current liabilities.
44
www.tekcapital.com 2.14
Share capital
Ordinary Shares
Ordinary shares are classified as equity.
Share premium
The share premium account has been established to represent the excess of proceeds over the nominal value for all share issues, including
the excess of the exercise share price over the nominal value of the shares on the exercise of share options as and when they occur.
Incremental costs directly attributable to the issue of new ordinary shares and new shares options are shown in equity as a deduction, net
of tax, from the proceeds.
Merger Reserve
The consolidated financial statements are accounted for using the ‘pooling of interests’ method’, which treats the Group as if it had been
combined throughout the current and comparative accounting periods. Pooling of interests principles for this combination gave rise to a
merger reserve in the consolidated statement of financial position, being the difference between the nominal value of new shares issued by
the Company for the acquisition of the shares of the subsidiary and the subsidiary’s own share capital.
Non-controlling interest
Non-controlling interest is the portion of equity ownership in a subsidiary not attributable to the parent company.
2.15
Trade payables
Trade payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from suppliers.
Accounts payable are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of business if
longer). If not, they are presented as non-current liabilities.
Trade payables are recognised initially at fair value and subsequently measured at amortised cost using the effective interest rate method.
2.16
Share based payments
The Group operates a number of equity-settled, share-based compensation plans, under which the entity receives services from employees
as consideration for equity instruments (options) of the Group. The fair value of the employee services received in exchange for the grant of
options is recognised as an expense. The total amount to be expensed is determined by reference to the fair value of the options granted:
•
including any market performance conditions;
•
targets and remaining an employee of the entity over a specified time period); and
excluding the impact of any service and non-market performance vesting conditions (for example, profitability, sales growth
•
excluding the impact of any non-vesting conditions (for example the requirement of the employees to save).
Assumptions about the number of options that are expected to vest include consideration of non-market vesting conditions. The total
expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At
the end of each reporting period, the entity revises its estimates of the number of options that are expected to vest based on the non-
market vesting conditions. It recognises the impact of the revision to the originally estimates, if any, in the income statement, with a cor-
responding adjustment to equity.
When the options are exercised, the Group issues new shares. The proceeds received net of any directly attributable transactions costs are
credited to share capital (nominal value) and share premium when the options are exercised.
45
NOTES TO THE FINANCIAL STATEMENTS
2.17
Current and deferred tax
The tax expense for the year comprises current and deferred tax. Tax is recognised in the consolidated income statement, except to the
extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, the tax is also recognised in other
comprehensive income or directly in equity, respectively.
The current income tax charge is calculated on the basis of tax laws enacted or substantively enacted at the balance sheet date in the
countries where the Company and its subsidiaries operate and generate taxable income. Management periodically evaluates positions
taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where
appropriate on the basis of amounts expected to be paid to the tax authorities.
Deferred income tax is recognised on temporary timing differences arising between the tax bases of assets and liabilities and their carrying
amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial
recognition of goodwill; deferred income tax is not accounted for if it arises from initial recognition of an asset or liability in a transaction
other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss.
Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date
and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.
Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the
temporary differences can be utilised.
Deferred income tax liabilities are provided on taxable temporary differences arising from investments in subsidiaries except for deferred
income tax liability where the timing of the reversal of the temporary difference is controlled by the Group and it is probable that the
temporary difference will not reverse in the foreseeable future.
Deferred income tax assets are recognised on deductible temporary differences arising from investments in subsidiaries only to the extent
that it is probable the temporary difference will reverse in full in the future and there is sufficient taxable profit available against which the
temporary difference can be utilised.
Deferred income tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax
liabilities and when the deferred income tax assets and liabilities relate to income taxes levied by the same taxation authority on either the
same taxable entity or different taxable entities where there is an intention to settle balances on a net basis.
2.18
Provisions
Provisions and any other anticipated foreseen liabilities are recognised: when the Group has a present legal or constructive obligation as a
result of past events; it is probable that an outflow of resources will be required to settle the obligation; and the amount has been reliably
estimated. Restructuring provisions comprise lease termination penalties, and employee termination payments. Provisions are not
recognised for future operating losses.
Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering
a class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the
same class of obligations may be small. Provisions are measured at the present value of the expenditures expected to be required to settle
the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the
obligation. The increase in the provision due to the passage of time is recognised as an interest expense.
2.19
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the
lessee. All other leases are classified as operating leases.
Rentals payable under the operating leases are charged to income on a straight-line basis over the term of the relevant lease.
46
www.tekcapital.com 2.20
Revenue recognition
Revenue is measured at the fair value of the consideration received or receivable, and represents amounts receivable for the services supplied,
stated net of discounts, and value added taxes. The Group recognises revenue when the amount of revenue can reliably be measured; when
it is probable that future economic benefits will flow to the Group; and when specific criteria have been met for each of the Group’s activities,
as described below. The Group bases its estimate of return on historical results taking into consideration the type of customer, the type of
transaction and the specifics of each arrangement.
The Group also recognises an unrealised profit/loss on the revaluation of investments in share of portfolio companies in accordance with the
fair value policy outlined in Note 2.9.
Provision of services
Income is derived from the provision of services either when a report is issued to the client; or when a specialist fee is incurred for the transfer
of rights to intellectual property where a client has acquired IP from a report. Revenue is recognised when a service has been provided.
Sales of goods
Income is derived from the sale of goods when the goods have been shipped to the customer
Interest income
Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable.
3.
Financial Risk Management
3.1
Financial risk factors
(a)
Portfolio Risk
The fair value of each portfolio company represents the best estimate at a point in time and may be impaired if the business does not perform
as well as expected, directly impacting the Group’s value and profitability. This risk is mitigated as the size of the portfolio increases. The Group
performed sensitivity analysis with regards to assumptions used in determination of fair value of the portfolio in Note 11.
(b)
Credit Risk
Credit risk is managed on a Group basis. In order to minimise this risk, the Group endeavours to only deal with companies that are
demonstrable creditworthy, and the Directors continuously monitor the exposure.
(c)
Liquidity Risk
Cash flow forecasting is performed on a Group basis. The Directors monitor rolling forecasts of the Group’s liquidity requirements to ensure it
has sufficient cash to meet operational needs. At the reporting date the Group held bank balances of US $1,165,442. All amounts shown in the
consolidated statement of financial position under current assets and current liabilities mature for payment within one year, with Trade and
Other Receivables exceeding Trade and Other Payables by US$ 142,916.
(d)
Financial risk management
The Company’s Directors review the financial risk of the Group. Due to the early stage of its operations the Group has not entered into any
form of financial instruments to assist in the management of risk during the period under review.
(e)
Market risk
Due to low value and number of financial transactions that involve foreign currency and the fact that the Group has no borrowings to man-
age, the Directors have not entered into any arrangements, adopted or approved the use of derivative financial instruments to assist in the
management of the exposure of these risks. It is their view that any exchange risks on such transactions are negligible.
47
NOTES TO THE FINANCIAL STATEMENTS
(f)
Foreign exchange risk
Foreign exchange risk arises when individual Group entities enter into transactions denominated in a currency other than their
functional currency. The Group’s policy is, where possible, to allow Group entities to settle liabilities denominated in their functional
currency, with the cash generated from their own operations in that currency. Where Group entities have liabilities denominated in a
currency other than their functional currency (and have insufficient reserves of that currency to settle them), cash already denominated
in that currency will, where possible, be transferred from elsewhere within the Group.
A sensitivity analysis has been performed to assess the exposure of the Group to foreign exchange movements. If the exchange rate
weakened by 10 percent then the effect on the loss before tax would increase by US$34,977 and equity would decrease by US$37,711.
(g)
The vote by the United Kingdom (UK) to leave the European Union (EU)
The vote by the United Kingdom (UK) to leave the European Union (EU) (referred to as Brexit), increases potential for uncertainty and
disruptions that may lead up to and follow Brexit, including with respect to volatility in exchange rates and interest rates and potential
material changes to the regulatory regime applicable to our operations in the UK. Brexit could adversely affect European or worldwide
political, regulatory, economic or market conditions and could contribute to instability in global political institutions, regulatory agen-
cies and financial markets. This could have an adverse effect on our business, ability to raise additional capital, financial results and
operations.
3.2
Capital management
The Group’s objectives when managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide
returns for shareholders, benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.
In order to adjust or maintain the capital structure, the Group may adjust the level of dividends paid to its shareholders, return capital
to shareholders, issue new shares or sell assets to reduce borrowings. The Group has no external borrowings. This policy is periodically
reviewed by the Directors, and the Group’s strategy remains unchanged for the foreseeable future.
The capital structure of the Group consists of cash and bank balances and equity consisting of issued share capital, reserves and re-
tained losses of the Group. The Directors regularly review the capital structure of the Company and consider the cost of capital and the
associated risks with each class of capital. The Company has no external borrowings and this has no impact on the gearing levels of the
Group as at 30 November 2018.
The Company’s historic cost of capital has been the cost of securing equity financings, which have averaged around 10%. The company’s
long-term financial goal is to optimise its returns on invested capital (ROIC) in excess of our weighted average cost of capital (WACC)
and as such create value for our shareholders. The method the Company seeks to employ for achieving this is to utilise its structural
intellectual capital developed through its Discovery Search Network, its Invention Evaluator service and its Vortechs Group Service to
mitigate selection bias and improve returns on invested capital. Ultimately, management will seek to monetize these returns with exits
from its investments in portfolio companies.
4.
Critical accounting estimates and judgements
Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of
future events that are believed to be reasonable under the circumstances. The Directors made the following judgements:
- determination as to the classification of the Group as an investment entity as discussed in Note 2.4
- determination of operating segments as disclosed in Note 5
- determination of reliance of the Group’s portfolio companies on funding to achieve their fair values discussed in Note 11.
The Directors also make estimates and assumptions concerning the future. The resulting accounting estimates will by definition, seldom
equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the
carrying value of the assets and liabilities within the next financial year are detailed below.
48
www.tekcapital.com Key estimate
area
Key assumption
Valuation of
unquoted
equity invest-
ments
Useful life
of Invention
Evaluator
website
Useful life
of Vortechs
Group
In applying valuation techniques to determine the fair value of unquoted equity investments
the Company makes estimates and assumptions regarding the future potential of the invest-
ments. The Group’s policy is to value new portfolio companies at cost of the acquired IP or
equity plus associated expenses to facilitate the acquisition. Existing portfolio companies are
valued using either a market transaction such as third-party funding or, in the absence of a
recent market transaction, by alternative methods and where appropriate by an external, quali-
fied valuation expert
The fair value of Guident Limited reflects the fair value of Guident’s net assets. This value is
primarily based on the US patent 9,429,943 valued using royalty relief method. The estimates
used in this valuation include market size and market penetration used to determine projected
sales, the royalty relief rate and the discount factor. These estimates are key to calculation of the
net present value of future cashflows of costs avoided under the Royalty Relief method applied
when valuing the patent.
The fair value of Salarius Limited reflects the fair value of Salarius’ net assets. This value is pri-
marily based on the US patent 8,900,650 valued using royalty relief method. The estimates used
in this valuation include market size and market penetration used to determine projected sales,
the royalty relief rate and the discount factor. These estimates are key to calculation of the net
present value of future cashflows of costs avoided under the Royalty Relief method applied
when valuing the patent.
The fair value of Lucyd Limited reflects the fair value of Lucyd’s net assets. This is primarily
based on the following identifiable assets:
-
cashflows associated with the e-shop. Key assumptions used in estimating future cash flows are
projected profits including market size and market penetration used to determine projected
sales, estimated cost of sales and overhead costs and a discount factor applied for the net
present value of estimated future cashflows from the platform.
-
Lucyd’s token value determined based on the number of tokens held multiplied by
the 30 November 2018 closing token price. Key assumption used in finalizing the tokens valua-
tion included discount factor applied for the token’s price volatility and liquidity of the market..
The Directors have considered the useful life of the Invention Evaluator website to be indefinite
because of the uniqueness of the service it provides and that there is no competitor in the
market in which the Group operates who is able to provide a similar service. The Directors
undertake an annual review that considers an appropriateness of the use of an indefinite useful
life in addition to impairment review and if required make a provision in the financial
statements.
The Directors have considered the useful life of Vortechs Group to be indefinite because of the
ongoing service revenue that is being generated. The business operates in a specialised market,
with few competitors. The Directors undertake an annual review that considers an
appropriateness of the use of an indefinite useful life in addition to impairment review and if
required make a provision in the financial statements.
Lucyd’s ecommerce platform valued by estimating the net present value of future
Share based
payment
The estimate of share based payments costs requires the Directors to select an appropriate
valuation model and make decisions about various inputs into the model including the
volatility of its own share price, the probable life of the options and the risk free interest rate.
Potential im-
pact within
the next
financial
year
Potential
impact in
the longer
term
Note refer-
ence for
sensitivity
analysis
Note 11
Note 12
Note 12
Note 24
49
NOTES TO THE FINANCIAL STATEMENTS
Key esti-
mate/judg-
ment area
Deferred
Taxes
Key assumption
Deferred tax is the tax expected to be payable or recoverable on differences between the
carrying amounts of assets and liabilities in the financial statements and the corresponding tax
bases used in the computation of taxable profit, and is accounted for using the balance sheet
liability method. Deferred tax assets are recognised to the extent that it is probable that taxable
profits will be available against which deductible temporary differences can be utilised. The
carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to
the extent that it is no longer probable that sufficient taxable profits will be available to allow all
or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected
to apply in the period when the liability is settled or the asset is realised based on tax laws and
rates that have been enacted or substantively enacted at the balance sheet date. The Group did
not recognize deferred tax liability on fair value gains associated with the revaluation of shares
in its portfolio companies due to availability of the substantial shareholdings exemption. This is
considered a permanent difference and not a temporary difference.
Potential
impact within
the next
financial year
Potential
impact in
the longer
term
Note refer-
ence for
sensitivity
analysis
Note 20
5.
Segmental reporting
The Directors consider the business to have three segments for reporting purposes under IFRS 8 which are:
•
•
•
professional services, including the provision of recruitment services via Vortechs Group, provision of reports and services
provided to locate and transfer technologies to customers, as well as R&D tax relief credits and provision of management
services to its portfolio companies
licencing and investment activities, including acquiring licences for technologies, portfolio company investment, development
and commercialisation
product sales (relevant only for first 5 months of the year ended 30 November 2017, due to deconsolidation of Belluscura plc as
of May 1, 2017)
• other, including activities not captured in any of the above categories. See also note below the table.
50
www.tekcapital.com
Included in the “Other” in the year ended 30 November 2017 are non product sales related expenses of Belluscura Limited. Due to
deconsolidation 2017 these activities are no longer recognised in the Group’s Consolidated Statement of Comprehensive Income.
6. Expenses
6.1 Expenses by nature
Included in the Other administration expenses is the amount of US$ 66,632 related to payments under operating lease for the office
rental agreement also referenced in Note 23.
6.2 Auditor remuneration
51
NOTES TO THE FINANCIAL STATEMENTS
7. Employees
7.1 Director’s emoluments
The highest paid Director received a salary of US$191,865 (2017: US$159,410) and benefits of US$15,253 (2017L US$18,719). The
highest paid Director received a bonus of US$0 (2017: US$191,865). The highest paid Director did not exercise any share options or
receive any shares from the Company during the current year.
7.2
Employee benefit expenses
7.3 Average number of people employed
To enhance flexibility and improve cost control, the Group utilizes consultants for scientific review, administrative and operations support,
software development and other knowledge-intensive services.
52
www.tekcapital.com
8. Income tax expense
The tax on the Group’s loss before tax differs from the theoretical amount that would arise using the weighted average tax rate
applicable to losses.
The weighted average applicable tax rate was 17% (2017: 20%). The increase is caused by a standard amount of tax payable in those
States in the USA which a subsidiary company operates from and is not attributable to the level of profits or losses incurred.
Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty over the recoverability of
those losses through future profits.
9.
Earnings per share
Basic earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of
Ordinary Shares outstanding during the period.
Diluted earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the sum of weighted average
number of (1) Ordinary Shares outstanding during the period and (2) any dilutive potential Ordinary Shares outstanding at 30 November
2018.
53
NOTES TO THE FINANCIAL STATEMENTS
10. Investments in subsidiaries
Tekcapital Europe Ltd and Tekcapital LLC are still recognised as subsidiaries of Tekcapital plc because they continue to provide advisory
services in IP search and technology transfer.
54
www.tekcapital.com * As at the year end, the Group initiated liquidation of three portfolio companies, allowing capital to be allocated to projects with higher
potential returns.
As at the year end, the Company has no interest in the ownership of any other entities or exerts any significant influence over or provides
funding which constitutes an “unconsolidated structured entity”.
All UK subsidiaries are exempt from the requirement to file audited accounts by virtue of section 479A of the Companies Act 2006.
55
NOTES TO THE FINANCIAL STATEMENTS
11.
Financial Assets at Fair Value through Profit and Loss
Group’s investments in portfolio companies in the years ended 30 November 2018 and 30 November 2017 are listed below and classified
as equity instruments. The principal place of business for portfolio companies listed below is US and UK.
Total fair value gain of $5.8m for the year reflects uplift in value of shares of Guident and Salarius, offset mostly by reduction in valuation
of Lucyd Limited. Considering early stage of commercialisation, fair value of remaining portfolio companies was recorded based on the
cost of acquired IP, as their carrying amounts represent a reasonable approximation of fair value.
The Group closed three portfolio companies, allowing capital to be allocated to projects with higher potential returns.
The valuation techniques used fall under, Level 2 – Observable techniques, other than quoted prices, and Level 3- Other techniques as
defined by IFRS 13. These techniques were deemed to be the best evidence of fair values considering early stage of portfolio companies.
There has been no transfer between levels during the period. Fair value measurement hierarchy for financial assets as at 30 November
2018 with comparative amounts as of 30 November 2017:
56
www.tekcapital.com Guident ($8.5m gain)
For the 6 months ended 31 May 2018, the Group recorded the fair value of Guident Ltd based on the cost of recently acquired IP. How-
ever due to commercialisation advancements as of 30 November 2018, an external valuation by an independent patent valuation expert
was prepared for US patent 9,429, 943. The total fair value of $8.5m reflects the fair value of Guident’s net assets as determined by:
•
Valuation of US patent 9,429,943 of $10.3m conducted by an external, qualified valuation expert using the Income Approach,
Royalty Relief Method. Following valuation inputs were applied by the valuation expert:
-
Total US market size of $35b for autonomous vehicles and drones (as the patent applies to both) for the 12 years
period ended 30 September 2033. 1% market penetration of Guident’s patent starting in 2021 with annual increase of
1% leading to a 12% market penetration by 2033, resulting in projected $3b in sales of drones/vehicles underlying
licensing revenue between 2021 and 2033. This market penetration assumption is based on a number of factors:
o
o
Broad protection and claims included in the IP
The protection given to the product by its US patent, which effectively gives Guident a barrier to entry in the
US through 2033
The strength and experience of the management team, whose proven expertise is in the exact areas required
to bring the product to market and build the brand;
There are no foreseeable software development barriers in the commercialisation process
Other foreseeable challenges for directors to deliver successful commercialisation appear to be well
within the abilities of directors to handle.
o
o
o
-
-
-
-
Total 5.375% license royalty rate, with 3% royalty attributable to the university and 2.375% comprising Guident’s
licencing revenue based on comparable market transactions
Corporate income tax rate of 17% applied to projected licensing costs saved at an 18% discount rate which was used
to discount proceeds as determined by opportunity cost (10%), inflation rate (3%) and technology risk (5%)
The deferred tax liability of ($1.7m) recorded by Guident based on UK corporate tax rate of 17% applied to the fair
value gain associated with the patent
Net book value of other assets and liabilities of <(0.1m).
Salarius ($0.9m gain)
Due to commercialisation advancements as of 30 November 2018, compared to fair value as of 30 November 2017 determined based on
the cost of acquired IP, an external valuation by an independent patent valuation expert was prepared for US patent 8,900,650.
The fair value of $0.9m reflects the fair value of Salarius’ net assets as determined by:
•
Valuation of US patent 8,900,650 of $1.1m conducted by an external, qualified valuation expert using the Income Approach,
Royalty Relief Method. Following valuation inputs were applied by the valuation expert:
-
Projected underlying revenue from sales of table salt and low sodium salt (i.e. excluding any potential additional salty
snacks market opportunities) of $73.9m for the 11-year period ended in 2030. Market penetration of 0.143% in 2019
growing to 1.7% in 2030. This market penetration assumption is based on a number of factors:
o
o
Microsalt is a unique product substantially in advance of alternative, developed, and tested in terms of
market acceptability and ready to market;
The protection given to the product by its US patent, which effectively gives Salarius a barrier to entry in the
US for 11 more years;
57
NOTES TO THE FINANCIAL STATEMENTS
o
o
o
The strength and experience of the management team, whose proven expertise is in the exact areas required
to bring the product to market and build the brand;
There are no foreseeable manufacturing barriers in the commercialisation process. Manufacturing will be
outsourced, and it can be clearly foreseen that this is deliverable;
Other foreseeable challenges for management to deliver successful commercialisation appear to be well
within the abilities of management to handle.
-
-
Licence royalty rate of 7.8% with 3% royalty attributable to the university and 4.8% comprising Salarius’ licencing
revenue based on comparable market transactions
13% discount rate used to discount proceeds as determined by opportunity cost (10%) and inflation rate (3%).
Technology risk was determined at 0%, as the patent describes easily manufactured salt compositions, maybe
manufactured in many production facilities without extensive modifications. The end product has already been
manufactured and used to conduct consumer acceptance tests.
The deferred tax liability of $0.2m recorded by Salarius based on UK corporate tax rate of 17% applied to the fair value gain
associated with the patent
Net book value of liquid assets, creditors and debtors of <($0.1m).
•
•
Change in estimate of the fair value of the patent was effectuated in the valuation as of 30 November 2018 compared to 31 May 2018.
The change pertained to the addition of 3% royalty rate attributable to the university as well as further increase in the discount rate.
Lucyd Ltd ($3.0m loss)
The fair value of $3.0m reflects the fair value of Lucyd’s net asset as determined by:
•
•
•
Valuation of following Lucyd’s significant assets performed by an external, qualified valuation expert:
-
Lucyd’s e-commerce platform selling advanced and fashionable eyewear valued at $2.1m as determined by applying
an 18% discount rate on $5m of gross profit projected through 2022. The 18% discount rate was calculated as a total
of 10% opportunity cost, 3% inflation rate and 3% technology risk
Lucyd’s 44.5m LCD tokens held in treasury valued at $0.6m based on the observable price of $0.0376, discounted by
66% for market discount to reflect market’s volatility and liquidity
Lucyd’s trademarks valued at $0.2m, assessed using Cost Approach Reproduction Method. Through cost analysis, the
fair value approximates cost recognized in Lucyd’s balance sheet
-
-
The deferred tax liability of $0.4m recorded by Lucyd based on UK corporate tax rate of 17% applied to the fair value gain
associated with the ecommerce platform
Net book value of creditors, debtors and liquid assets of $0.5m.
Lucyd will be re-valuated in subsequent reporting periods. The future value of Lucyd could fluctuate significantly, either up or down,
based on the performance of the business, the achievement of product development milestones and the change in the value of the Lucyd
token (LCD), amongst others.
Belluscura ($0.4m loss)
The Group contributed over $0.5m in two private placements held in February and November 2018, each at 13 pence per share. The fair
value of the holding declined by $0.4m due to the most recent private placement held at 10 pence per share in December 2018. The
Group did not participate in the December 2018 placement.
Non Invasive Glucose Tek/ eGravitas/ Frigidus ($0.3m loss)
The Group closed these three portfolio companies resulting in recognition of a $0.3m fair value loss.
Smart Food Tek/ eSoma (Nil Gain / Nil loss)
Under level 3 unobservable inputs. In the absence of observable inputs the directors have considered the entities own data to determine
the fair value, which equates to the original funds invested. They do not consider that any other available information would materially
change or give a more reliable representation of the value.
58
www.tekcapital.com
Description of significant unobservable inputs to valuation:
The significant unobservable input used in the fair value measurements categorised within Level 3 of the fair value hierarchy, together
with a quantitative sensitivity analysis as at 30 November 2018 are shown as below:
No sensitivities have been included on the other investments as their fair value equates to cost.
The Group exercised judgment in determination of sufficiency of portfolio companies’ cash reserves, forecasts and ability to raise money
to achieve their fair values. Directors reviewed and questioned the forecasts used, standing liquidity and working capital balances, as
well as discussed capability and plans to raise money in the future with directors or management of portfolio companies. Based on the
review, the Group made a positive determination as to porfolio companies likely ability to achieve fair values considering liquidity factors.
59
NOTES TO THE FINANCIAL STATEMENTS
12. Intangible assets
The intangible assets presented above are included within Professional Services segment under Note 5 disclosure.
Under IAS38, the Group’s Invention Evaluator is regarded by the Directors as being an intangible asset with an indefinite useful life. The
Directors believe that the asset is unique in that no competitor offering currently exists, the service is already proven to have appealed
globally to many types of clients including Fortune 100 companies, there is no expectation of obsolescence in the foreseeable future, and
the service from the use of the asset generates sufficient ongoing revenue streams. The Directors have carried out an impairment review
and believe that the value in use is significantly greater than book value.
The Directors have considered the recoverable amount by assessing the value in use by considering the future cash flow projections
of the revenue generated by the Invention Evaluator intangible, cash flows were based on the past revenue generation plus expected
growth. The projections were assessed for a three year period in order to determine no impairment.
Under IAS38, the Group’s Vortechs asset is regarded by the Directors as being an intangible asset with an indefinite useful life. The
Directors believe that this asset is unique as it operates in a niche market, it generates an ongoing revenue stream, and there is no
expectation of obsolescence. This asset meets the requirements of IAS38 as it is:
-
-
-
-
Separately identifiable
The Group controls this asset
Future economic benefits flow to the Group in the form of service revenues from this asset
The cost of this asset can be measured reliably
The Directors have carried out an impairment review and consider the value in use to be greater than the book value.
The Directors have considered the recoverable amount by assessing the value in use by considering the future cash flow projections of
the revenue generated by the Vortechs intangible, cash flows were based on the past revenue generation plus expected growth. The
projections were assessed over a period in excess of 5 years on the basis the directors consider the projections can be reasonably
forecast. The tech-transfer recruiting is viewed by directors as permanent part of the Group’s business and its offering. This together with
the high turnover in this industry leading to continuous hiring needs leads Directors to apply projections of over 5 years in the
impairment determination.
60
www.tekcapital.com 13. Property, furniture and equipment
61
NOTES TO THE FINANCIAL STATEMENTS
14. Trade and other receivables
The fair value of trade and other receivables are not materially different to those disclosed above. The Group’s exposure to credit risk
related to trade receivables is detailed in Note 3 to the consolidated financial statements.
*The Group and the Company hold two convertible loans issued by its portfolio company, Salarius Ltd during the year for the total of US$
350,000, of which US$250,000 was drawn. Both loan notes were issued at 10% coupon rate and included option to convert the debt into
shares at market price (no discount offered). Market rate of 10% was applied in determination of the present value of cash flows related
to both notes. Convertible loan issued in September 2018 issued for $50,000 is repayable on demand, however directors currently do not
anticipate the repayment before November 2019. The $300,000 note originated in October 2018 is payable by Salarius on 29 October
2020 or can be converted into Salarius’ equity upon occurrence of certain conversion events.
The Group had outstanding receivables from its portfolio companies as at 30 November 2018 in the amount of:
- US$220,732 due from Lucyd Ltd
- US$8,185 due from Salarius Ltd
- US$2,536 due from Guident Ltd
The Company recorded US$2,500,000 provision against its receivable from one its subsidiaries, Tekcapital LLC.
15. Cash and cash equivalents
62
www.tekcapital.com 16. Categories of financial assets and financial liabilities
17. Share capital and premium
Share capital
The shares have full voting, dividend and capital distribution (including on winding up) rights; they do not confer any rights of
redemption. The following shares were issued during the year: October 2018 - 11,698,335 shares were issued in the placing of new
ordinary shares at £0.075p. Total proceeds of US$1,097,216 were netted against cost of raising finance in the amount of US$149,509.
The Company has authorised share capital of 55,150,957, with a nominal value of £0.004. Of these shares, 54,353,042 were issued and
fully paid up.
63
NOTES TO THE FINANCIAL STATEMENTS
Share premium
18. Reserves
Retained earnings
Retained earnings
Merger reserve
Translation reserve
64
www.tekcapital.com 19 . Trade and other payables
The fair values of trade and other payables are not materially different to those disclosed above.
The Group’s exposure to currency and liquidity risk related to trade and other payables is detailed in note 3 to the accounts.
20.
Deferred income tax
Unused tax losses for which no deferred tax assets have been recognised is attributable to the uncertainty over the recoverability of
those losses through future profits. A tax rate of 17% has been used to calculate the potential deferred tax.
21.
Dividends
No dividend has been recommended for the year ended 30 November 2018 (2017: Nil) and no dividend was paid during the year (2017:
Nil).
65
NOTES TO THE FINANCIAL STATEMENTS
22. Cash used from operations
23. Commitments
Capital commitments
The Group entered into convertible loan note agreement in November 2018 with Salarius Ltd for the total amount of $300,000. $200,000
was provided as part of the agreement by the Group in November 2018, with $100,000 commitment remaining outstanding.
Operating lease commitments
The Group’s subsidiaries have various office rental agreements. The total unprovided minimum lease commitments under non-
-cancellable operating leases are:
24. Share based payments
The Group operates an approved Enterprise management scheme and an unapproved share option scheme.
The fair value of the options granted is expensed over the vesting period and is arrived at using the Black-Scholes model. The
assumptions inherent in the use of this model are as follows:
The share based payment expense for the year was $30,204 (2017: $70,318). Details of the number of share options and the weighted
average exercise price outstanding during the year as follows:
66
www.tekcapital.com *The weighted average exercise price for the options exercisable as at 30 November 2018 and 30 November 2017 was £0.33p and
£0.23p respectively
The weighted average remaining contractual life is 1.82 years (2016: 2.56 years).
The weighted average fair value of options granted during the year was £0.07p (2017: £0.04p)
The range of exercise prices for options outstanding at the end of the year was £0.081p - £0.46p (2017: £0.19p - £0.46p)
25.
Related party transactions
During the year Nigel Wray and his family participated in a Belluscura Private Placements held in January 2018 and November 2018.
Nigel Wray and his family’s participation was 4.5m shares (15.14% ownership) as of 30 November 2018. As a holder of more than 10%
of both the Company’s issued share capital and Belluscura’s issued share capital at the time of the relevant transactions, Nigel Wray and
his family were deemed a related party under the AIM Rules for Companies and therefore this transaction was a related party transaction
pursuant to those rules.
Details of Directors’ remuneration and grant of options are given in the Directors’ report. The Group had an outstanding payable balance
to Max Inglis in the amount of US$193 and $7,486 payable to Dr Clifford Gross as at 30 November 2018.
The Group has taken advantage of the exemption in IAS 24 “related parties” not to disclose transactions with other Group companies.
26.
Events after the reporting period
On December 4, Belluscura plc completed private placement at 10p. The Group did not participate in this placement.
On December 6, 2018, Guident ltd appointed Johan De Nysschen as a director. Johan previously served as Executive Vice President of
General Motors and President of the Cadillac Motor Division, President of Infiniti Motor Company Ltd, President of Audi of America Inc.,
and President of Audi Japan, amongst other positions.
On January 14, 2019, Guident ltd appointed Daniel Grossman as a director. He most recently served as CEO of Chariot. Previously, Dan
helped create General Motors’ mobility division, Maven, and led all operations as COO, and was a Vice President at Zipcar, where he
helped pioneer the brand globally.
On February 19, 2019, Belluscura plc filed an additional patent application entitled “Improved Extracorporeal Membrane Oxygenation
Device, System and Related Methods,” which involves incorporating and expanding their existing oxygen enrichment patent portfolio into
an innovative, next generation portable artificial lung and a novel wound care treatment device.
67
STAY IN TOUCH
John Eccles House
Robert Robinson Avenue
Oxford Science Park
Oxford, OX4 4GP
United Kingdom
U.K.: +44 (0) 1865 338102
U.S. : +1 (305) 200-3450
E-mail: info@tekcapital.com
www.tekcapital.com